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Matriksin	metalloproteinaasit	ja	niiden	estäjät	biomarkkereina	
ulseratiivisessa	koliitissa	ja	Crohnin	taudissa
Tiivistelmä
Matriksin metalloproteinaasit (MMP) muodostavat 23 metalloendopeptidaasin perheen, 
jotka yhdessä kykenevät hajottamaan kaikkia soluväliaineen rakenneosia. Ne on yhdistetty 
useisiin tulehduksellisiin tapahtumiin, kuten nivelrikkoon, valtimonrasvoittumistautiin, jopa 
syöpiin. MMP:t osallistuvat myös suotuisiin tapahtumiin, kuten epiteelirikon korjaamiseen. 
MMP:iden toimintoja estävät niiden spesifit kudosestäjät, TIMP:t.
Tässä tutkimuksessa olemme tarkastelleet suolen limakalvoa kroonisissa tulehduksellisissa 
suolistosairauksissa (IBD). Tavoitteenamme on ollut luokitella ja kuvata tulehdusta paitsi suo-
len limakalvolla myös autoimmuunitauteihin yhdistetyssä ihon haavassa, pyoderma gangreno-
sumissa (PG), jonka samanlaisuutta IBD-tulehduksen kanssa olemme pyrkineet arvioimaan. 
Olemme tutkineet MMP:itä ja TIMP:itä pääasiallisesti paksusuolen limakalvolla aikuisten 
Crohnin taudissa (CD), lasten CD:ssa ja haavaisessa paksusuolen tulehduksessa (UC) sekä 
määrittämättömässä koliitissa (IC). Olemme arvioineet myös nuoruusiässä puhjennutta tautia 
sairastavia henkilöitä, joilta paksusuoli on poistettu. Heiltä olemme tutkineet ohutsuolesta 
tehdyn ulostesäiliön  limakalvoa ja pyrkineet luonnehtimaan sen MMP-profiilia. Tutkimuk-
sen keskeisenä tavoitteena on ollut löytää tiettyjä MMP:itä, jotka voisivat toimia markkereina 
tulehduksellisen suolistosairauden erotusdiagnostiikassa, sekä tunnistaa limakalvovaurioon li-
ittyviä MMP:itä, joita vastaan voisi mahdollisesti käyttää MMP-estäjiä. Kaikki tutkimukset 
on toteutettu immunohistokemiallisin menetelmin.
 
Tuloksista näemme, että immunosuppressoivat lääkkeet vähensivät MMP-9:n ja MMP-26:n 
ilmentymistä Crohnin tautia sairastavien aikuispotilaiden suolen limakalvolla. Nämä MMP:t 
voisivat mahdollisesti toimia MMP-estäjien kohteina Crohnin taudin hoidossa. Sen sijaan las-
ten paksusuolen tulehduksessa MMP-10 ja TIMP-3 näyttäytyvät mahdollisina markkereina 
IBD-tulehdukselle ja MMP-7 markkerina Crohnin taudille. Paksusuolen poiston läpikäynei-
den potilaiden ohutsuolen säiliön limakalvon MMP-profiilin ei voitu näyttää olevan selkeästi 
IBD- tai ei-IBD-tyyppistä. Tässä tutkimuksessa kuitenkin ensimmäistä kertaa osoitetaan 
MMP-3:n, MMP-7:n, MMP-9:n, ja MMP-12:n, sekä TIMP-2:n ja TIMP-3:n ilmentym-
inen ohutsuolisäiliön limakalvolla.  PG:n MMP-profiili muistutti osin IBD:n tulehtunutta 
limakalvoa. PG:n tulehduksessa on kuitenkin piirteitä myös ihon tulehduksesta.
Näihin tutkimuksiin pohjautuen, MMP:t ja niiden estäjät vaikuttavat lupaavilta apuvälineiltä 
tulehduksellisen suolistosairauden erotusdiagnostiikassa ja luokittelussa. Lisäksi useiden 
MMP:iden ilmentyminen ohutsuolesta rakennetussa säiliössä osoitettiin nyt ensimmäisen 
kerran. Nämä löydökset lisäävät tietämystä tulehduksellisen suolistosairauden limakalvon ja 
pyoderma gangrenosumin tapahtumista.
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Matrix	metalloproteinases	and	their	tissue	inhibitors	as	biomarkers	
in	ulcerative	colitis	and	Crohn’s	disease
Abstract
Matrix metalloproteinases (MMPs) represent a family of 23 metalloendopeptidases, collec-
tively capable of degrading all components of the extracellular matrix. MMPs have been im-
plicated in several inflammatory processes such as arthritis, atherosclerosis, and even carcino-
mas. They are also involved in several beneficial activities such as epithelial repair. MMPs are 
inhibited by endogenous tissue inhibitors of matrix metalloproteinases (TIMP).
In this study, MMPs were investigated in intestinal mucosa of inflammatory bowel diseases 
(IBD), chronic intestinal disorders. The main focus was to characterize mucosal inflammation 
in the intestine, but also cutaneous pyoderma gangrenosum (PG), to assess similarites with 
IBD inflammation. MMPs and TIMPs were mainly examined in colonic mucosa, in adult 
Crohn’s disease (CD), and paediatric CD, ulcerative colitis (UC), and indeterminate colitis 
(IC). Ileal pouch mucosa of proctocolectomized paediatric onset IBD patients was also inves-
tigated to characterize pouch mucosa. The focus was on finding specific MMPs that could act 
as markers to differentiate between different IBD disorders, and MMPs that could be implied 
as markers for tissue injury, potentially serving as targets for MMP-inhibitors. All examina-
tions were performed using immunohistochemistry.
The results show that immunosuppressive agents decrease stromal expression of MMP-9 and 
-26 that could serve as specific targets for MMP-inhibitors in treating CD. In paediatric 
colonic inflammation, MMP-10 and TIMP-3 present as molecular markers for IBD inflam-
mation, and MMP-7 for CD. MMP expression in the the pouch mucosa could not be clas-
sified as strictly IBD- or non-IBD-like. For the first time, this study describes the expression 
of MMP-3, -7, -9, -12, and TIMP-2 and -3 in pouch mucosa. The MMP profile in PG bears 
resemblance to both intestinal IBD inflammation and cutaneous inflammation.
Based on the results, MMPs and their inhibitors emerge as promising tools in the differential 
diagnosis of IBD and characterization of the disease subtype, although further research is nec-
essary. Furthermore, the expression of several MMPs in pouch has been described for the first 
time. While further research is warranted, the findings contribute to a better understanding of 
events occurring in IBD mucosa, as well as pyoderma gangrenosum.
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1. Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) belong to a spectrum of inflammatory bowel 
diseases (IBD). The etiopathology of these chronic diseases is unknown, but the accepted hy-
pothesis is that they arise in response to commensal bacteria in genetically prone individuals, 
whereby excessive T-lymphocyte immune response in the gut occurs. In indeterminate colitis 
(IC), features of both disorders exist and differential diagnosis between the two conditions can 
not be made. IBD is more common in Western countries, and its incidence is rising, in both 
in the adult and paediatric populations. 
Although CD and UC share similarities, treatment is somewhat different between the two. If 
medical treatment – conventional immunosuppressants or anti-TNF-α-agents – are not suf-
ficient, in UC, surgical removal of the colon is curative. In CD, where inflammation may also 
affect small intestine, surgery is not necessarily curative. Still, complications such as strictures 
or fistulas, or unresponsiveness to medical treatment may necessitate surgery. Children with 
CD pose special challenges, as in paediatric patients, inflammation often presents solely in 
the colon and differential diagnosis between UC and CD may be challenging. Changing the 
diagnosis from UC to CD in follow-up is not rare in children.
Matrix metalloproteinases (MMPs) make up a family of 23 zinc-dependent enzymes. To-
gether they can degrade almost all components of the extracellular matrix (ECM) and base-
ment membrane (BM). They can active and regulate the activation of several growth factors 
and cytokines, and take part in pathological events in the gut as well as in normal physiologi-
cal processes. Tissue inhibitors of metalloproteinases inhibit MMPs by binding covalently to 
them, but have also been suggested to have roles independent of MMPs.
In IBD, MMPs have been associated with mucosal damage and events such as leucocyte mi-
gration and angiogenesis. MMP-9 is the most ample MMP in IBD, and inhibition of MMP-
9 and MMP-3 has been suggested to have a beneficial role. MMP-3 and MMP-7 have been 
found to correlate with the severity of disease, as well as TIMP-1.
Pyoderma gangrenosum (PG), is a cutaneous wound linked to several systematic disorders, 
but still of unkown etiology. Although a skin manifestation, IBD accounts for up to 20% of 
the underlying systemic diseases, and this sparked an interest in inflammatory bowel disease. 
This work tries to bring light to the intestinal profiles, more specifically to matrix metallopro-
teinases and their inhibitors related to IBD, both in children and adults. The objective was to 
increase understanding of the mechanisms behind IBD, ultimately enabling better care.
In this thesis, the mucosal MMP and TIMP profiles of paediatric IBD and adult CD were 
examined. In addition, ileal pouch mucosa in proctocolectomized UC patients with paediatric 
onset disease was investigated. The aim was to find biomarkers implicative of tissue injury or 
characteristic of a specific IBD type. The findings in IBD were compared to those in PG, a 
skin disorder presenting as a wound and associating with the presence of IBD.
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2. Review of Literature
“The individual cell is very highly dependent on its battery of MMPs to control its environment, to 
move through it, and to maintain its protective cocoon” (Woessner JF Jr 1998).
2.1.	Matrix	Metalloproteinases
Matrix metalloproteinases are a family of 23 human zinc-dependent endopeptidases (Nagase 
H 2006) and they share a similar gene arrangement (Arakaki PA 2009). There are 24 genes 
to code metalloproteinases, but genes for MMP-23 are duplicated (Nagase H 2006). Even 
though the two are encoded by different genes, the amino acid sequences of both MMP-23A 
and MMP-23B are the same (Overall CM 2002). These metalloproteinases are important in 
dedgrading extracellular matrix and basement membrane, but their repertoire extends beyond 
these functions: MMPs also cleave substrates such as chemotactic molecules, growth factors, 
cell surface receptors and cell-adhesion molecules, taking part in important processes such 
as altering cell motility, modulating bioactivity of chemokines and regulating apoptosis (Ta-
ble 1.) (Cawston TE 2006, Clark IM 2008, Egeblad M 2002). Most MMPs are secreted as 
inactive precursors (zymogens, pro-MMPs), and are activated in tissue by cleavage by other 
proteinases (Murphy G 1997, Egeblad M 2002, Nagase H 2006). MMPs such as MMP-11 
and -14 are activated intracellularly (Nagase H 1999).
MMPs can be separated into 6 main classes according to their substrate specificity, cellular lo-
cation and primary structure: collagenases, gelatinases, stromelysins, matrilysins, membrane-
type MMPs and others (Visse R 2003, Nagase H 2006). Another method is to group them 
according to domain structure (Figure 1.) (Cawston TE 2006, Nagase H 1999). MMPs are 
constructed of generally 5 different domains: a signal peptide, a propeptide, a catalytic domain 
with the zinc-binding site, a hinge region, and – in most cases – a hemopexin-like domain 
(Clark IM 2008, Visse R 2003, Cawston TE 2006, Parks WC 2004, Nagase H 2006). Some 
members have additional domains, whereas matrilysins and MMP-23 lack the hemopexin-
domain (Parks WC 2004, Nagase H 2006). MMP-23 has an IgG-like domain preceded by 
a cysteine rich domain (Visse R 2003). The signal peptide directs secretion from the cell 
(Egeblad M 2002), and the propeptide maintains enzyme latency (Nagase H 2006, Egeblad 
M 2002). The catalytic domain consists of a structural zinc-ion, essential for enzymatic activ-
ity (Nagase H 1999, Egeblad M 2002). The hinge region is a linker peptide, and connects the 
catalytic domain and hemopexin, but its function is not yet fully understood (Nagase H 1999). 
Hemopexin is required to cleave triple helical interstitial collagens (Nagase H 1999).
MMPs play important roles in several physiological and pathological processes. While MMPs 
are important in events such as embryonic development, longitudinal growth of bones (Caw-
ston TE 2006), killing pathogenic bacteria (Parks WC 2004), and epithelial repair (Parks WC 
2004), they are also implicated in disease mechanisms such as in arthritis (Cawston TE 2006), 
several cardiovascular diseases, for example in the development of abdominal aortic aneurysms 
(Nagase H 2006), and in cancer, regulating apoptosis, angiogenesis and invasion and metasasis 
(Egeblad M 2002). 
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Figure 1.  MMP structure. This research was originally published in the Journal of Bio-
logical Chemistry. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 
1999;274:21491-4. © the American Society for Biochemistry and Molecular Biology.
2.1.1. Collagenases (MMP-1, MMP-8)
MMP-1 (collagenase 1, interstitial collagenase, human skin fibroblast collagenase)
MMP-1 was the first MMP to be identified, found in the metamorphosing tadpole (Gross J 
1962). It was also the first vertebrate collagenase that was both purified as a protein and cloned 
as cDNA (Bauer EA 1970, Golberg GI 1986). Expression of MMP-1 is found in several cell 
types; macrophages, fibroblasts, endothelial cells, chondrocytes, osteoblasts and keratinocytes 
(Moscatelli D 1980, Welgus HG 1981, Otsuka K 1984, Welgus HG 1985, Lefebre V 1990, 
Saarialho-Kere UK 1993), and signals such as IL-1ß, PDGF and TNF-α upregulate expres-
sion of this collagenase (Unemori EN 1991). MMP-1 degrades molecules such as collagens 
type I, II, and III, gelatin, α1-antitrypsin, entactin, tenascin, aggrecan, and pro-MMP-1 (Wel-
gus HG 1981, Birdedal-Hansen H 1993, Sang QA 1996a). Pro-MMP-1 can be activated by 
several enzymes, such as trypsin, kallikrein, and plasmin (Birkedahl-Hansen H 1993). In cuta-
neous wounds, basal migrating keratinocytes express MMP-1 mRNA and protein (Saarialho-
Kere UK 1993, Vaalamo M 1996), induced by factors such as type I collagen in dermal matrix 
(Sudbeck BD 1997). Expression ceases when re-epithelialization is complete (Saarialho-Kere 
UK 1995a). Collagenase is suggested to play a role in the removal of dermal tissue, dissociate 
keratinocytes from dermal matrix and promote migration over the matrix (Saarialho-Kere 
UK 1993, Vaalamo M 1996), and maintain directionality of re-epithelialization (Pilcher BK 
1997).
MMP-8 (collagenase 2, neutrophil collagenase)
Although MMP-8 was first described in 1968 in polymorphonuclear leucocytes (Lazarus 
GS 1968), it was cloned and expressed as a pure protein in 1990 (Hasty KA 1990). It cleaves 
collagen types II and III, but is selective towards collagen type I (Hasty KA 1987). MMP-8 
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is expressed primarily in neutrophils (Weiss SJ 1989), but also in cells such as monocytes/
macrophages, inflamed bronchial epithelial cells (Prikk K 2001), chondrocytes (Tetlow LC 
2001), and gingival epithelial cells and plasma cells (Kiili M 2002). Unlike other collagenases, 
MMP-8 synthesis is already completed in neutrophils during granulocyte precursor cell dif-
ferentiation in the bone marrow ( Jeffrey JJ 1998). It is the predominant MMP in healing and 
non-healing cutaneous wound fluid (Nwomeh BC 1999). MMP-8-null male mice produce 
larger numbers of skin papillomas sooner after treatment with chemical carcinogen, possibly 
due to a sustained inflammatory response (Balbin M 2003). MMP-8 could also have a protec-
tive effect in humans, regulating tumour metastasis (Montel V 2004). 
2.1.2. Gelatinases (MMP-9)
MMP-9 (gelatinase B, 92kDa gelatinase, type V collagenase)
In 1974, a neutral proteinase from human neutrophils was purified, and it was capable of de-
grading denaturated collagens (gelatins) (Sopata I 1974). The precise structure of this MMP 
was not determined until 1989, in transformed human lung fibroblasts (Wilhelm SM 1989). 
MMP-9 precursor is activated by plasmin, trypsin, α-chymotrypsin, cathepsin G, and MMPs, 
such as MMP-3 and MMP-10 (Okada Y 1992, Nakamura H 1998, Lijnen HR 2001). Deg-
radation by MMP-9 is not restricted to gelatins. MMP-9 also cleaves ECM components such 
as types IV and V collagen (Wilhelm SM 1989), aggrecan (Fosang AJ 1992), elastin (Senior 
RM 1991), and other substances like IL-1ß and substance P (Backstrom JR 1995, Ito A 
1996). Expression is found in several cells, such as macrophages, smooth muscle cells (Lijnen 
HR 2001), chondrocytes (Tetlow LC 2001), eosinophils, neutrophils (Stahle-Backdahl M 
1993), and endothelial cells (Nguyen M 2001). Several pathological processes exhibit MMP-
9. It is associated with malignant progression in human cutaneous melanoma (MacDougall JR 
1995), inhibition of apoptosis in a model of human colon adenocarcinoma (Meyer E 2005), 
and it correlates with metastatic phenotype in cancer cell lines (Bernhard EJ 1990). Interest-
ingly, in a murine model, factors such as TGF-ß1, IL-1ß, and TNF-α enhance expression of 
MMP-9 in metastatic colon carcinoma cells (Shimizu S 1996).
2.1.3. Stromelysins (MMP-3, MMP-10)
MMP-3 (Stromelysin-1, transin, proteoglycanase,collagenase-activating protein [CAP])
Non-collagenolytic metalloprotease activity was seen in rabbit synovial fibroblasts in 1974 
(Werb Z 1974), and in human articular cartilage the same year (Sapolsky AI 1974).This 
stromelysin was characterized in humans in rheumatoid synovial fibroblasts (Okada Y 1986). 
In chronic wounds, MMP-3 mRNA and protein are present in basal keratinocytes in the 
proliferating area of epidermis near the wound edge (Saarialho-Kere UK 1994). Other cells 
such as endothelial cells (Herron GS 1986), macrophages (Welgus HG 1990), fibroblasts 
(Saarialho-Kere UK 1994, Wilhelm SM 1987) and chondrocytes (Tetlow LC 2001) also 
produce MMP-3. In MMP-3 deficient mice, processes such  as impaired wound healing due 
to a defect in wound contraction (Bullard KM 1999), and reduced chondrocyte derived mac-
rophage-chemotactic activity (Haro H 2000a) occur. On the other hand, MMP-3 deficient 
mice also show reduced neutrophil influx as well as less severe damage in immune-mediated 
lung injury (Warner RL 2001). MMP-3 can enhance the activation of other MMPs, such as 
MMP-9 and MMP-1 (Suzuki K 1990, Ogata Y 1992). 
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MMP-10 (stromelysin-2, transin 2)
This MMP was first described in humans in 1988, in a cDNA library in adenocarcinomas 
(Muller D 1988). MMP-10 is expressed in basal keratinocytes at the migrating front in the 
same cells that produce MMP-1 (Saarialho-Kere UK 1994), and over-expression in transgen-
ic mice enhances apoptosis of wound edge keratinocytes, as well as disorganization of migrat-
ing epithelium (Krampert M 2004). It is also expressed in migrating epithelial cells in corneal 
wounds (Daniels JT 2003), and MMP-10 mRNA is found in migrating enterocytes (Vaalamo 
1998). MMP-10 mRNA production is induced by factors such as IFN-γ, KGF, EGF, TNF-α 
and TGF-ß1 (Madlener M 1996, Kerkela E 2000). Invasiveness of fibroblast-like synovio-
cytes in rheumatoid arthritis correlates positively with expression of MMP-10 mRNA in 
these cells (Tolboom TC 2002). While expression in epithelial skin cancers is found, it does 
not associate with invasiveness in these cancers, but may be induced due to associated ulcera-
tive actions or inflammatory matrix remodelling (Kerkela E 2001a). MMP-10 has been impli-
cated in resistance to proapoptotic signals in a model of human colon adenocarcinoma (Meyer 
E 2005). Stromelysin-2 is found in developing human bone in osteoblasts and osteoclast, and 
it possibly plays a part in resorption of bone at specific cellular sites (Bord S 1998).
2.1.4. Human Metalloelastase (MMP-12)
MMP-12 (metalloelastase, human metalloelastase [HME] , macrophage elastase)
Elastolytic activity was noted in mouse macrophage-conditioned media in the 1970s (Werb 
Z 1975), but it was not until 1992 that this MMP was identified as an independent member 
of the MMP-family (Shapiro SD 1992). Soon after, human MMP-12 was cloned from a 
cDNA library of human alveolar macrophages (Shapiro SD 1993). MMP-12 can be activated 
by several factors, such as plasmin (Carmeliet P 1997). Metalloelastase can degrade a number 
of ECM components such as fibronectin, laminin, entactin, type IV collagen, but it does not 
cleave interstitial collagens (Gronski TJ Jr 1997). In addition to macrophages, MMP-12 is 
found in fibroblasts, smooth muscle cells (Woodside KJ 2003), and chondrocytes (Kerkelä 
E 2001b), and has been implicated in pathological processes such as cartilage degradation 
( Janusz MJ 1999) and airway damage (Hautamäki RD 1997). Churg et al (2003) propose 
that MMP-12 results in emphysema by releasing TNF-α, an important player in IBD (Ap-
ostolaki M 2010). Transformed keratinocytes express MMP-12 in skin cancers, and it has 
been suggested to play a role in epithelial dedifferentiation and invasiveness (Kerkelä E 2000). 
MMP-12 generates angiostatin from plasmin, and in this manner inhibits proliferation of 
endothelial cells and tumour growth (Cornelius LA 1998). Indeed, MMP-12 mRNA expres-
sion in hepatocellular carcinoma associates with improved survival (Gorrin Rivas MJ 1998).
2.1.5. Matrilysins (MMP-7, MMP-26)
MMP-7 (matrilysin-1, pump-1)
Matrilysin-1 cDNA was first isolated in an effort to clone genes related to stromelysin, by 
screening a human tumour library (Muller D 1988). Like MMP-26, it lacks the hemopexin 
domain (Uria JA 2000). The MMP can degrade several ECM components such as fibronectin, 
gelatins, collagen type IV, laminin, elastin, vitronectin, and proteoglycan aggrecan in cartilage 
(Woessner JF Jr 1988, Miyazaki K 1990, Murphy G 1991, Fosang AJ 1992, Imai K 1995). It 
is found in several cancers in humans (Pajouh MS 1991, Heppner KJ 1996, Honda M 1996), 
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and correlates with tumour invasion (Honda M 1996). However, it is also detected in normal 
human tissue, specifically epithelium, such as in the endometrium (Rodgers WH 1993) and 
in the stomach (Honda M 1996). Macrophages in atherosclerotic lesions also express MMP-
7 (Halpert I 1996). Although MMP-7 is not found in healthy epidermis, or in skin wounds 
(Saarialho-Kere 1993, Vaalamo M 1996), it is present in exocrine glands (Saarialho-Kere 
1995b). MMP-7 is found in healthy airway epithelium and both mRNA and protein expres-
sion is increased in cystic fibrosis (Dunsmore SE 1998). Migrating cells in epithelial cells in 
wounded trachea show greater MMP-7 expression, and it is suggested to be a factor in tissue 
repair (Dunsmore SE 1998). Interestingly, factors such as TNF-α increase MMP-7 mRNA 
expression (Marti HP 1992). MMP-7 can cleave TNF-α from its membrane bound precursor 
form from the cell surface, producing soluble bioactive TNF-α (Mohan MJ 2002), and in this 
way possibly promote apoptosis (Ii M 2006). Also, macrophage-derived MMP-7 release of 
TNF-α is critical for macrophage action on herniated disc resorption (Haro H 2000b).
MMP-26 (matrilysin-2, human endometase)
Matrilysin-2 is presently the smallest MMP, and like matrilysin-1, lacks the hemopexin do-
main (Uria JA 2000). It was cloned by three different laboratories within a short period of 
time: in human placental (Uria JA 2000), foetal (de Coignac AB 2000) and endometrial tu-
mour cDNA (Park HI 2000). It hydrolyses substrates such as type IV collagen, gelatin, fi-
brinogen, fibronectin and α1-proteinase inhibitor and is capable of activating pro-MMP-9 
(Uria JA 2000, Park HI 2000). It does not cleave triple-helical collagens such as collagens type 
I and type II (Uria JA 2000). It exists in migrating keratinocytes during wound repair (Ahokas 
K 2005) and also in healthy intestine (Bister VO 2004). MMP-26 mRNA has been identified 
in several other healthy human tissues such as the kidneys, brain, spleen, prostate, as well as in 
cancer cell lines of epithelial origin such as prostate, lung, and breast (Marchenko GN 2001). 
Although it may have a role in normal physiological processes (Park HI 2000), expression of 
matrilysin-2 associates with invasiveness and decreased survival (Zhao YG 2004, Yamamoto 
H 2004). 
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Table 1. MMPs and their substrates investigated in this study. (Modified From Egeblad M 
2002, Sang QA 1996a).
 
 MMP Substrates
 MMP-1
Collagens type (I, II, III, VII, VIII, X, XI), gelatins, aggrecan, 
entactin/nidogen, brevican, fibronectin, IGFBP, laminin, link protein, 
myelin basic protein, tenascin, vitronectin, α1-antichymotrypsin, α2-
macroglobulin, α1-proteinase inhibitor, C1q, casein CXCL12, fibrin, 
fibrinogen, IL-1ß, L-selectin, pro-MMP-2, and -9, pro-TNF-α.
 MMP-3
Collagens (type III, IV, V, VII, IX XI), gelatins, aggrecan, brevican, 
decorin, elastin, entactin/nidogen, fibrillin, fibronectin, fibulins, IGFBP, 
laminin link protein, myelin basic protein, osteonectin, osteopontin, 
perlecan, tenascin, vitronectin, α-1-proteinase inhibitor, ADAMTS-1, C1q, 
CCL7, CXCL12, E-cadherin, fibrin, fibrinogen, pro-HB-EGF, IL-1ß, L-
selectin, pro-MMP-1, -7, -8, -9, -13, NC1 fragment of collagen XVIII, PAI-
1, plasminogen, substance P, T kininogen, pro-TNF-α, uPA
 MMP-7
Collagens (type I, IV), gelatins, aggrecan, brevican, decorin, elastin, 
entactin/nidogen, fibronectin, fibulins, laminin, link protein, myelinbasic 
protein, osteonectin, osteopontin, tenascin, vitronectin, α1-proteinase 
inhibitor, C1q, casein, E-cadherin, FAS ligand, fibrinogen, pro-HB-EGF, ß4 
integrin, pro-MMP-1, -2, -9, plasminogen, pro-TNF-α
 MMP-8
Collagens (type I, IV) aggrecan, brevican, α2-macroglobulin, α1-proteinase 
inhibitor, ADAMTS-1, C1q, fibrinogen, substance P
 MMP-9
Collagens (type IV, V, XI, XIV), gelatins, aggrecan, decorin, elastin, 
fibrillin, IGFBP3, laminin, link protein, myelin basic protein, osteonectin, 
vitronectin, α2-macroglobulin, α1-proteinase inhibitor, casein C1q, CXCL1, 
CXCL4, CXCL7-precursor, CXCL12, endothelin, fibrin, fibrinogen, 
galectin-3, IL-1ß, IL-8/CXCL8 , IL-2Rα, c-kit ligand, pro-MMP-2, NC1 
fragment of collagen XVIII, plasminogen, substance P, latent TGF-ß, pro-
TNF-α
 MMP-10
Collagens (type III, IV, V), gelatins, aggrecan, brevican, elastin, fibronectin, 
link protein, casein, fibrinogen, laminin,                                pro-MMP-1, -7, 
-8, -9
 MMP-12
Collagens (type I, IV) gelatins, aggrecan, elastin, entactin/nidogen, fibrillin, 
fibronectin, laminin, myelin basic protein, vitronectin, α2-macroglobulin, α1-
proteinase inhibitor,  factor XII, fibrinogen, IgG, NC1 fragment of collagen 
XVIII, plasminogen, pro-TNF-α
 MMP-26
Collagen type IV, gelatin, fibrinogen, fibronectin, vitronectin, α1-proteinase 
inhibitor, casein, pro-MMP-9
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2.2.	Tissue	Inhibitors	of	Matrix	Metalloproteinases
Tissue inhibitors of matrix metalloproteinases (TIMP) make up a family of four inhibitors 
(TIMP-1, -2, -3 and -4) (Baker AH 2002). The sequence homology and protein structure 
share similarities in all four (Stetler-Stevenson WG 2008). They have two structural domains: 
an N-terminal and a C-terminal domain, both of which contain three conserved disulfide 
bonds (Visse R 2003, Nagase H 2006, Stetler-Stevenson WG 2008): the N-domain is re-
sponsible for inhibiting MMPs (Visse R 2003, Nagase H 2006, Stetler-Stevenson WG 2008). 
TIMPs are secreted, but can also be found on the cell surface in associaton with membrane-
bound proteins (Baker AH 2002). All members of the TIMP-family inhibit MMPs by form-
ing covalent 1:1 complexes (Lambert E 2004, Visse R 2003), and selective inhibition of some 
of the MMPs exists (Stetler-Stevenson WG 2008), such as the ability of TIMP-3 to inhibit 
more proteases belonging to the ADAM-family (Table 2.) (Stetler-Stevenson WG 2008).
The actions of TIMPs are not restricted to MMP-inhibition, and their effect depends on the 
cell context and model studied. TIMPs can modulate cellular processes such as cell growth, 
apoptosis and migration, and can be both anti- and protumourigenic (Visse R 2003, Lambert 
E 2004, Stetler-Stevenson 2008). They have embryogenic activity, but also inhibit angiogen-
esis (Lambert E 2004).
Table 2. TIMPs investigated in this study and proteinases inhibited. (Modified from Egeblad 
M 2002)
2.2.1. TIMP-1
TIMP-1 (tissue inhibitor of metalloproteinases-1, human collagenase inhibitor, fibroblast colla-
genase inhibitor, EPA-erythroid potentiating activity)
TIMP-1 was the first TIMP discovered, found in a medium of cultured fibroblasts (Bauer EA 
1975). It was later identified to be identical with the erythroid potentiating activity protein 
(Gasson JC 1985). TIMP-1 mRNA is found in a variety of cells such as keratinocytes, macro-
phages, endothelial cells, fibroblasts, and TIMP-1 production is suggested in smooth muscle 
cells and osteoblasts (Welgus HG 1983, Stricklin GP 1993). TIMP-1 is a weak inhibitor of 
MMP-14, -16, -24 and -19 (Nagase H 2006). Unlike the other TIMPs, TIMP-1 has no effect 
on tumour necrosis factor-α-converting enzyme (TACE) (Amour A 1998). However, TIMP-
1 is capable of inhibiting MMP-7, thus indirectly inhibiting the production of soluble TNF-α 
(Amour A 1998, Mohan MJ 2002). While TIMP-1 has growth inhibitory action (Taube ME 
2006), it can also promote cell growth as in smooth muscle cells and keratinocytes (Hayakawa 
 TIMP Proteinase inhibited
 TIMP-1
MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13, -17, -19, -25, -26,
ADAM-10, ADAMTS-4
 TIMP-2
MMP-1, -2, -3, -7, -8, -9, -10, -13, -14, -16, -17, -19, -24, -25, -26,
ADAMTS-4
 TIMP-3
MMP-1, -2, -3, -9, -13, -14, -16, -17, -19, -25, ADAM-10, -12, -17,     
ADAMTS-4, -5
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T 1992), independent of its actions on MMPs (Hayakawa T 1992, Taube ME 2006). TIMP-1 
can inhibit apoptosis independent of MMP-inhibition, for example in breast epithelial and 
Burkitt’s lymphoma cell lines (Li G 1999, Guedez L 1998). Antiapoptotic activity is not re-
stricted to tumour cells (Singla DK 2007). The role of TIMP-1 in tumour spread is complex, 
as it promotes micrometastasis in liver, simultaneously reducing the number of macrometas-
tases (Kopitz C 2007). Similarly, in Burkitt’s lymphoma, TIMP-1 initially promotes tumour 
growth, followed by regression of tumour associated with TIMP-1 inhibition of endothelial 
cell migration (Guedez L 2001). 
2.2.2. TIMP-2
TIMP-2 (tissue inhibitor of metalloproteinases-2, CHIAMP-chondrocyte-derived inhibitor of an-
giogenesis and metalloproteinase activity, CSC-21K)
While several factors can induce expression of other TIMPs, TIMP-2 expression seems to be 
constitutive (Lambert E 2004). Unlike the other TIMPs and contrary to its name, TIMP-2 
can either promote MMP-2 activation by interaction with MT1-MMP, or inhibit MMP-2 
activation directly (Stetler-Stevenson WG 2008). Although TIMP-2 is capable of weak inhi-
bition of TACE, it does not present as a physiologically relevant inhibitor (Amour A 1998). 
TIMP-2 reduces proliferation of cells such as microvascular endothelial cells, fibroblasts and 
tumour cell lines (Baker AH 1998, Stetler-Stevenson WG 2005, Stetler-Stevenson WG 
2008), whereas it can also promote proliferation of cells, for example, erythroleukemia cells, 
fibroblasts and keratinocytes (Hayakawa T 1994, Corcoran ML 1995). TIMP-2 promotes in-
vasiveness of human glioblastoma cell line (Lu KV 2004), but inhibits invasion of transformed 
human breast cells (Ahn SM 2004). In a mouse model, TIMP-2 can protect from colorectal 
cancer metastasis and reduce growth of existing metastases (Brand K 2000). 
2.2.3. TIMP-3
TIMP-3 (tissue inhibitor of metalloproteinases-3)
This protein was discovered as a transformation-sensitive protein bound to the ECM of 
chicken embryo fibroblasts (Blenis J 1984), and was later declared to be TIMP-3 (Pavloff 
N 1992). While the other TIMPs remain soluble, TIMP-3 interacts with sulphated gly-
cosaminoglycans and is sequestered into the ECM (Yu WH 2000). It is the only member 
of the TIMP-family likely to be a physiologically significant inhibitor of tumour necrosis 
factor-α-converting enzyme, TACE (a member of the ADAM-family) (Amour A 1998). In 
TIMP-3 null mice, increased activity of TACE and release of TNF-α occurs, leading to he-
patic inflammation and cell death (Mohammed FF 2004). Similarly, in lungs of TIMP-3 
null mice, spontaneous air space enlargement occurs, and in vitro, fibroblasts depict increased 
destruction of the extracellular matrix, perhaps due to an altered MMP/TIMP-balance (Leco 
KJ 2001). TIMP-3 has been demonstrated to have antiangiogenic capabilities (Qi JH 2003), 
and is suggested to have a role in hair growth and foetal development by regulating normal 
tissue turnover (Airola K 1998). TIMP-3 promotes apoptosis in tumour cell lines and smooth 
muscle cells, both independent of and dependent upon MMP-inhibition (Baker AH 1998, 
Ahonen M 2003). However, in TIMP-3 deficient mice, mammary epithelium depicted exten-
sive apoptosis (Fata JE 2001). In human colorectal cancer, expression of TIMP-3 protein is 
decreased, and is suggested to prevent proteolytic degradation and apoptosis (Zeng Z 2001). 
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In cutaneous wounds, TIMP-3 protein may be essential for re-epithelialization and stromal 
remodelling, and is found in proliferating keratinocytes and stromal cells in normally healing 
and chronic wounds (Vaalamo M 1999).
2.3	Structure	of	Intestinal	Mucosa
The human gastrointestinal tract begins at the mouth, then continues as the esophagus, the 
stomach, the small intestine, and the large intestine. The small intestine is divided into three 
parts: the duodenum, the jejunum and the ileum. The large intestine consists of the cecum, the 
ascending colon, the transverse colon, the descending colon, the sigmoid colon, the rectum, 
and the anal canal (Figure 2.). The small intestine is principally responsible for absorbing 
digested food, and the large intestine for reabsorption of water and electrolytes, as well as 
elimination of waste materials and remaining food. Walls of both the small and large intestine 
have four layers: the mucosa, the submucosa, the muscularis externa and the serosa (Ross MH 
2003). 
Figure 2. Human gastrointestinal tract. (Modified from Bode C 1997)
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The mucosa
The mucosa consists of a layer of epithelium, underlying connective tissue (lamina propria) 
and muscularis mucosae, an inner circular and outer longitudinal layer of smooth muscle. In 
the small intestine, 5 different types of epithelial cells can be found: enterocytes, goblet cells, 
Paneth cells, enteroendocrine cells, and M cells. The epithelium of the large intestine resem-
bles that of the small intestine, but Paneth cells are normally absent (Ross MH 2003). The 
epithelial cells sit on the basement membrane (BM), produced by both epithelial and stromal 
cells (Simon-Assman P 1995). It is composed of type IV collagen, proteoglycans, laminins, 
entactin and of BM-associated fibronectin and tenascin C (Beaulieu JF 1997, Ross MH 2003). 
The BM attaches the epithelial cells to the underlying connective tissue, the lamina propria 
(LP), and also takes part in epithelial cell growth and differentiation (Simon-Assman P 1995).
Enterocytes form the majority of epithelial cells in both the small and large intestine, absorb 
substances from the lumen and secrete digestive enzymes, water and electrolytes (Ross MH 
2003). Goblet cells produce mucus. Paneth cells secrete antibacterial granules and thus aid in 
regulating normal bacterial flora in the gut (Ross MH 2003). Enteroendocrine cells produce 
paracrine and circulating hormones, for example somatostatin (paracrine) and cholecystoki-
nin (circulating). M cells have microfolds that face the lumen, and endocytose foreign anti-
gens, such as micro-organisms. These foreign components are presented to T-lymphocytes 
(CD4+T), and so to the immune system. Cells in the epithelium originate from stem cells in 
the lower parts of the intestinal glands. All but Paneth cells migrate from the gland to the sur-
face or villi. The cells last for 5-6 days, after which they are shed into the gut lumen. However, 
enteroendocrine cells last for up to 4 weeks (Ross MH 2003).
The submucosa
The submucosa is made of connective tissue and adipose cells at some sites. The muscularis 
externa consists of two smooth muscle layers; an inner layer of circularly arranged cells, and an 
outer layer of longitudinally arranged cells. In the colon, the outer layer of muscularis externa 
has also more condensed longitudinal bands of smooth muscle, the teniae coli. The serosa is 
a layer of squamous epithelium and connective tissue beneath. However, the descending and 
ascending colon, the duodenum and rectum have only connective tissue, the adventitia, instead 
of serosa, as these parts of the intestine are attached to the abdominal and pelvic wall. The 
surface area of the small intestine is increased by villi, mucosa projecting into the gut lumen 
(Ross MH 2003) (Figure 3.).
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Figure 3. Microscopic view of the colon. This article was published in Medical Physiology, 
2nd edition, Binder HJ, Intestinal fluid and electrolyte movement, p.933-948, Copyright 
Saunders, an imprint of Elsevier Inc (2009).
 
34
2.4.	Inflammatory	Bowel	Diseases	and	IBD-related	Wounds
Inflammatory bowel diseases are chronic, inflammatory diseases of the intestine (Farrell RJ 
2002, Shanahan F 2002). They encompass a spectrum of chronic gastrointestinal diseases of 
unknown origin, and comprise ulcerative colitis (UC), Crohn’s disease (CD) and indetermi-
nate colitis (IC) where a definite diagnosis – of either UC or CD – cannot be made (Geboes 
K 2003). As many as 25% of cases may become manifest before the age of 20 years (Olivia-
Hemker M 2002, Kim SC 2004). In children, CD frequently presents solely in the colon, 
and UC is more extensive than in adults (Griffiths AM 2000, Turunen P 2009). In childhood 
and adolescence, IBD can have negative effects on important physiological processes such as 
growth. Growth failure can be an initial symptom of the disease, as well as present an ongoing 
problem (Hildebrand H 1994). Symptoms might not always be as characteristic such as lethargy 
and abdominal discomfort, and diagnosis can be delayed by several years (Sawczenko A 2003).
The etiology of IBD is not known, but is thought to arise in genetically susceptible individuals 
from an excessive response of the immune system – mediated by T cells – to enteric bacteria 
(Shanahan F 2002, Farrell RJ 2002, Podolsky DK 2002): environmental factors have also been 
implicated (Shanahan F 2002, Farrell RJ 2002).
UC and CD are related polygenic disorders; they share some susceptibility loci, but not all 
(Orchard TR 2000, Lees CW 2009). Familial prevalence exists, and the relative risk for a first 
degree relative to develop CD is 5-35 and in UC 10-15 times as high as the general popula-
tion (Russell RK 2004). First degree relatives of patients with CD also have an increased risk 
of developing UC and vice versa (Russell RK 2004). In monozygotic twins, concordance for 
CD can reach 58%, and for UC, 18%, whereas numbers are markedly lower for dizygotic twins 
(Orholm M 2000, Tysk C 1988). Heredity seems to be a more important factor in CD than 
in UC. Genes such as NOD2, ATG16L1 and IRGM associate with susceptibility to CD, 
whereas ECM1 and IL10 are specific to UC (Lees CW 2009). IL23 genes (IL23R, IL12B, 
STAT23 and JAK2) associate with susceptibility to both disorders (Lees CW 2009). Inter-
estingly, certain variants in the IL23R gene associate with specific phenotypes; a connection 
with UC exists, but also with ileal disease in CD (Duerr RH 2006). Further, a certain variant 
in the IL-1RA gene (IL-1RN*2) in UC is associated with pouchitis after ileal pouch-anal 
anastomosis (Carter MJ 2001).
IBD does not rely solely on genetics, and environmental factors have to be taken into ac-
count. Factors affecting the mucosal barrier are associated with setting off the disease, such 
as nonsteroidal anti-inflammatory drugs (NSAID) and antibiotics (Berg DJ 2002, Card T 
2004). Interestingly, smoking appears as a risk factor for developing CD, but it seems to have 
a protective effect against UC (Halfvarson J 2006, Mahid SS 2006). Recurrent gastrointestinal 
infections have been linked to both UC and CD (Halfvarson J 2006). The efforts to implicate 
specific bacteria in the development of IBD are controversial (Chiba M 1998a,b), but in a 
mice model, enteric bacteria both induce and maintain colitis (Rath HC 2001).
The incidence of both UC and CD has increased during the past decades in the Western 
world (Loftus EV Jr 1998, Loftus EV Jr 2000). In adults, incidence of CD decreases as the age 
of the population examined increases, but the incidence of UC remains relatively stable (Vind 
I 2006). In Finland, the incidence of paediatric onset IBD increased 2-fold between 1987 and 
2003 (Turunen P 2006).
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2.4.1. Ulcerative Colitis
Ulcerative colitis generally presents exclusively in the colon (Podolsky DK 2002), and inflam-
mation is restricted to the mucosa and submucosa (Crawford JM 2003). Characteristically, the 
rectum mucosa is inflamed, and inflammation proceeds proximally in the colon in a continu-
ous manner (Doherty GA 2009). While most adult patients present with left-sided disease, 
the level of colonic involvement varies (Farmer RG 1993, Solberg IC 2009), and even 70% 
may progress to pancolitis (Farmer RG 1993). In children, the disease presents most often as 
pancolitis (Turunen P 2006, Griffiths AM 2000, Gower-Rousseau C 2009). In endoscopic 
examination, the colonic lumen may be dilated (Crawford JM 2003), with diffuse erythema, 
friabilitity and loss of vascular pattern in the mucosa (NASPGHAN 2007). If pancolitis is 
not present, an abrupt line of demarcation should be visible between the normal and the af-
fected colon (NASPGHAN 2007). On microscopical examination, pseudopolyps, superficial 
ulcers and minor fibrosis may be found (Crawford JM 2003). Ulcers in UC are often multiple, 
resemble V-shaped clefts, with scarce inflammatory cells lining the cleft (Price AB 1978). 
Chronic inflammation results in crypt distortion, branching and atrophy, in villous transfor-
mation of mucosal surface, mucin depletion and basal lymphoplasmacytosis (NAPGHAN 
2007). In UC, crypt associated giant cells and granulomas can occur, whereas granulomas 
distant from crypts and isolated giant cells do not (Mahadeva U 2002, Guindi M 2004). It is 
important to note that findings such as oral ulcers, small anal fissures, patchiness of inflamma-
tion in colon, relative rectal sparing, and backwash ileitis do not exlude the diagnosis of UC 
(NASPGHAN 2007).
In mild to moderate proctitis, 5-aminosalicylic (5-ASA) suppositories may be used, with or 
without oral preparations (Travis SPL 2008). In left-sided colitis, oral and topical 5-ASA used 
in concert may be enough, but if the colonic inflammation becomes extensive, systemic corti-
costeroids should then be administered (Travis SPL 2008). Indeed, where standard medica-
tion is not sufficient, approximately 15% of adults will develop a severe state of disease (Kohn 
A 2004, Doherty GA 2009). Severe active colitis of any extent indicates intravenous corticos-
teroids, and patients intolerant of these can be administered intravenous cyclosporin (Travis 
SPL 2008). If the disease becomes refractory to intravenous steroids, surgical options should 
be considered, specifically if clinical wellbeing is compromised (Travis SPL 2008). In refrac-
tory disease, prior to colectomy, anti-TNF-α-agents have been shown to be effective in both 
adults and children; in as many as 55% in the latter (Kohn A 2004, Cucchiara S 2008, Turner 
D 2010). With this in mind, as often as every fourth paediatric UC patient faces colectomy 
(Turunen P 2009). The treatment of paediatric patients parallels that of adult patients, and the 
number of studies in paediatric patients groups in UC is limited.
2.4.2. Crohn’s Disease
Crohn’s disease is a chronic inflammatory disease that can occur in any region of the gastroin-
testinal tract, and inflammation is typically transmural (Crawford JM 2003). Abdominal mass 
and perianal disease may be present, while both are absent in ulcerative colitis (Podolsky DK 
2002). Characteristic intestinal manifestations include for example, narrowing of the intes-
tinal lumen, formation of fistulas, perforation, fibrosis and granulomas (Graham MF 1995, 
Podolsky DK 2002, Guindi M 2004). When IBD presents in the colon, specific indicators 
of CD are granulomas and transmural lymphoid hyperplasia/aggregates (Swan NC 1998, 
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Guindi M 2004). However, if granulomas are absent, endoscopical diagnosis is then based on 
the presence of discontinuos inflammation (skip lesions, with healthy mucosa in between), 
deep fissuring ulcers, and apthous lesions on normal mucosa (NASPGHAN 2007). In CD, 
fissures are characteristically narrow, lined with inflammatory cells and extend into muscle 
(Price AB 1978). Intestinal stricture formation due to excessive deposition of fibrous tissue 
occurs in CD patients (Alexander-Williams J 1990, Graham MF 1995). As in UC, dilata-
tion of the intestine may occur in CD (Crawford JM 2003). Microscopically, pseudopolyps 
may also be found (Crawford JM 2003), making the mucosal surface appear “cobblestoned” 
(NASPGHAN 2007).
In mildly active localized ileocecal disease, oral budesonide is the treatment of choice (Dignass 
A 2010). If inflammation becomes moderate, one could opt for other oral corticosteroids or 
combination with azathioprine or 6-mercaptopurine. If the disease is refractory to steroids, 
anti-TNF-α-agents should be considered early on (Dignass A 2010). In severe ileocecal and 
colonic inflammation, systemic corticosteroids or anti-TNF-α-agents with or without immu-
nomodulators should be used (Dignass A 2010). Although steroid-refractory disease may be 
treated with anti-TNF-α-agents, surgery should be considered as well if complications occur 
(Dignass A 2010). Operative treatment is common in CD, as about 80% of patients eventu-
ally require surgery (Van Assche G 2010). In childhood-onset disease, every third patient 
undergoes surgery within the first decade (Turunen P 2006). While there is no concensus on 
the best prevention of disease recurrence, prophylactic treatment includes pharmacological 
therapy with mesalazine, antibiotics, azathiopurine or mercaptopurine, and with anti-TNF-
α-agents (Van Assche G 2010). Without prophylactic treatment, the disorders reoccur within 
a year in as many as every fourth patient (Van Assche G 2010). 
In paediatric patients, CD most often affects the colon or ileocolon, and disease presentation 
in the upper gastrointestinal tract or small intestine is less common than in adults (Griffiths 
AM 2000, Turunen P 2009). Children may also suffer from delay in puberty and impaired 
linear growth, complications that are present in several chronic diseases (Ballinger AB 2003, 
Sentongo TA 2000, Stephens M 2001). In children, exclusive enteral nutrition and corticos-
teroids are both effective in inducing remission (Van Assche G 2010). However, corticoster-
oids should not be used as a maintenance therapy due to the lack of proper response in adults 
to long-term treatment, and to their adverse effects on growth and bone metabolism (Van As-
sche G 2010). If the disease is resistant to pharmacological treatment, the disease is localized 
or growth is compromised, surgery should be considered (Van Assche G 2010).
2.4.3. Indeterminate Colitis
Differential diagnosis of IBD may be challenging. The term indeterminate colitis was intro-
duced in the 1970s to refer to IBD cases where there was difficulty in differentiating between 
UC and CD, and was originally used only for resected surgical samples (Price AB 1978). 
However, the term has been extended to IBD occurring in the colon without proper diagnosis 
of either UC or CD (Guindi M 2004, NASGPHAN 2007), and is not solely a histopatho-
logic diagnosis (Guindi M 2004, Geboes K 2003). Challenges in differential diagnosis are not 
rare. In adults, a prevalence of IC of 3-10% is found (Shivananda S 1996, Matsui T 2003), 
but in children, even a prevalence of 30% has been reported (Carvalho RS 2006). Possible ex-
planations for the high numbers of IC cases are diverse challenges to traditional classification 
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methods, for example gastroduodenal involvement occurring in UC (Valdez R 2000, Tobin 
JM 2001). Similarly, in colonic inflammation, instead of normal findings of UC in the colon, 
rectal sparing, ulcers and transmural inflammation may be present (Price AB 1978, Talbot 
IC 2005). Ulcerations can be intermittent, resembling skip lesions found in CD (Price AB 
1978). Paediatric patients present special challenges in diagnosis, as solitary small intestine 
involvement in CD is rare, but isolated colonic disease is common instead (Turunen P 2006). 
Interestingly, the proportion of IC is greater in very young IBD patients, but seems to decrease 
as children grow and reach adolescence and adulthood (Turunen P 2006). Although as many 
as half of IC cases are later re-diagnosed as either UC or CD (Turunen P 2006), this form of 
colitis – which can be very aggressive - has been proposed to be a separate clinical phenotype 
(Geboes K 2003, Carvalho RS 2006). 
2.4.4. Pouchitis
Paediatric UC patients tend to have more aggressive and extensive disease than adults (Lang-
holz E 1997, Griffiths AM 2000, Turunen P 2009, Pakarinen MP 2009). Surgery is necessary, 
in many cases, often performed in the early stages of disease (Turunen P 2006). The number 
of patients requiring proctocolectomy - within a decade after diagnosis - may reach 24% (Tu-
runen P 2009). Today, restorative proctocolectomy with straight ileoanal anastomosis (SIAA) 
or ileal pouch-anal anastomosis (IPAA) is the treatment of choice in paediatric medically 
unresponsive disease (Seetharamaiah R 2009), and both procedures seem to have similar out-
comes, although contradictory reports exist (Rintala RJ 1996, Durno C 1998, Seetharamaiah 
R 2009). In both SIAA, and IPAA, the ileal reservoir is often affected by pouchitis, an idi-
opathic inflammatory condition (Hoda KM 2008, Seetharamaiah R 2009). This acute inflam-
mation is a frequent complication after surgery (Perrault J 1997, Durno C 1998, Lepistö A 
2003, Hahnloser D 2007), occurring in as many as 73% of pediatric patients during a ten-year 
follow-up (Pakarinen MP 2009). It may present with increased stool frequency and liquidity, 
fever, abdominal cramping, and rectal bleeding (Coran AG 2004). However, only about 5% of 
patients with pouchitis develop chronic mucosal inflammation requiring regular medication 
with antibiotics, and pouchitis rarely leads to excision of the pouch (Keränen U 1997, Lepistö 
A 2002). The etiology and mechanisms behind pouchitis are not known, but it has been as-
sociated with events such as overgrowth of commensal bacteria in the pouch (Shen B 2005), 
faecal stasis, nutritional deficiencies and ischemia (Sandborn WJ 1994, Schmidt CM 1998). 
Factors such as extraintestinal manifestations of UC (specifically primary sclerosing cholan-
gitis) (Penna C 1996), perinuclear antineutrophil cytoplasmic antibodies (pANCA) (Kuisma 
J 2004, Fleshner PR 2001), NSAID use (Achkar JP 2005), backwash ileitis (Schmidt CM 
1998), extensive colonic disease preoperatively (Schmidt CM 1998), and young age at proc-
tocolectomy, predispose to pouchitis (Coffey JC 2009). Similarly, the rare HLADRB1*0103 
allele – also proposed to predict extent and severity of disease in UC (Roussomoussatakaki M 
1997, Ahmad T 2003) – is associated with the risk of pouchitis (Merrett MN 1992).
The incidence of pouchitis is higher in UC than in familial adenomatous polyposis (FAP) 
(Lohmuller JL 1990, Perrault J 1997, Lovegrove RE 2006), and it is proposed to be a recurrent 
form of colitis (Lohmuller JL 1990, Coffey JC 2009). Some suggest that pouchitis is a novel 
presentation of inflammatory bowel disease (IBD) (Shepherd NA 1987). Although mucosa is 
normal in the terminal ileum at the time of proctocolectomy, histopathological changes take 
place in the reservoir mucosa (Moskowitz RL 1986, Shepherd NA 1987, de Silva HJ 1991). 
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Colonic metaplasia develops in pouch mucosa, and while it is more prounounced in pouchitis, 
metaplasia is of a higher degree in chronic than in episodic pouchitis (Luukkonen P 1994). 
Colon-like mucosa replaces the ileal pouch mucosa, perhaps allowing the initial disease to 
recur. As the incidence of UC is rising (Turunen P 2006, Benchimol EI 2009), resulting in 
greater numbers of colectomized patients, it seems reasonable to assume that the incidence of 
pouchitis will also grow. 
2.4.5. Diagnostic Challenges
As discussed with IC, diagnosing IBD can be very challenging. In paediatric patients, as many 
as 15% are reported to be rediagnosed (Mamula P 2002), usually changing the diagnosis from 
UC to CD or IC (Mamula P 2002, Turunen P 2009). Rediagnosis is not rare even after proc-
tocolectomy, with as many as 12% of patients shifting diagnosis from UC to CD (Pakarinen 
MP 2009). A similar difficulty is found in adults, and studies cite that 6-15% of patients who 
underwent IPAA, had their  diagnosis changed from IC to CD (Yu CS 2000, Delaney CP 
2002). However, the difficulty of diagnosing is not only related to differential diagnosis within 
the IBD-spectrum of disease. In a paediatric cohort, 27% of patients were rediagnosed as CD 
after first presenting with (non-IBD) focal active colitis (Xin W 2003).
2.4.6. IBD-associated Dysplasia
Long-standing IBD is associated with an increased risk of colorectal cancer (CRC) (Bern-
stein CN 2001, Munkholm P 2003, Lakatos PL 2008), and it is estimated that CRC ac-
counts for approximately 15% of IBD patient deaths (Munkholm P 2003). Although CRC 
does not always occur in patients with a history of IBD (Danese S 2010), IBD is ranked as 
the third highest risk condition for this cancer, surpassed only by familial polyposis and he-
reditary non-polyposis colorectal cancer (Kulaylat MN 2010). CRC associated with IBD is 
generally diagnosed 15-20 years earlier compared to sporadic cancers (Lakatos PL 2008), and 
typically develops from flat dysplastic mucosa, whereas sporadic cancers mostly develop from 
polyps (Rhodes JM 2002). CRC in IBD is thought to arise through chronic inflammation, 
and factors such as TNF-α and IL-6 have been linked to development of these malignancies 
(Danese S 2010). Genetic elements have also been proposed as risk factors for CRC (Rhodes 
JM 1996), as well as the extent and duration of IBD, and the severity of histologic bowel in-
flammation (Lakatos PL 2008). Interestingly, risk of carcinoma is not uniform for both CD 
and UC, as is the case for small intestinal carcinoma which CD patients are more prone to 
develop (Bernstein CN 2001). IBD has also been associated with non-intestinal cancers such 
as haematological malignancies (Bernstein CN 2001).
2.4.7. Extraintestinal Manifestations
Both ulcerative colitis and Crohn’s disease have similar symptoms, like abdominal pain, diar-
rhoea, fever, rectal bleeding, and weight loss, and may present with malnutrition (Podolsky 
DK 2002, NASPGHAN 2007). Some extraintestinal manifestations (EIM) (Table 3.) are 
seen more often in IBD patients with specific HLA alleles (Williams H 2008). Presumably, 
genetic susceptibility is present in all cells, and exposure to a stimulus at a non-intestinal site 
may be the reason for EIMs occurring in IBD (Isaacs KL 2008). In fact, the DRB1*0103 
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allele associated with the severity of UC and the risk of pouchitis (Merrett MN 1992, Rous-
somoussatakaki M 1997, Ahmad T 2003), also associates with arthritis (Wordsworth P 2000). 
Extraintestinal manifestations can be complications due to medication or the original disease, 
such as pancreatitis, or they may be related to the activity of the underlying IBD, such as skin 
manifestations ( Jose FA 2009). Although present in both disorders, there seems to be a higher 
prevalence of EIMs in CD versus UC (Veloso FT 1996, Lakatos L 2003, Vind I 2006). 
Table 3. Extraintestinal manifestations of IBD. (Modified from Jose FA 2006, Evans PE 2007, 
Veloso FT 1996, Lakatos L 2003, BallingerAB 2003)
2.4.7.1 Pyoderma Gangrenosum
Pyoderma gangrenosum, PG, was first descibed in 1930 (Brunsting L 1930). PG is a neu-
trophilic dermatosis, where a nodule or pustule on the skin breaks and forms a painful enlarg-
ing ulcer (Ruocco E 2009, Callen JP 1998, Su WP 2004, Crowson AN 2003). Within the 
ulcer is excessive neutrophilic inflammation, haemorrage and epidermal necrosis (Callen JP 
1998), and surrounding the ulcer is an erythematous halo (Su WP 2004, Ruocco E 2009). 
There may be several lesions, and they often progress rapidly (Callen JP 1998). Incidence is 
low, with only 3-10 new cases a year per million people (Ruocco E 2009). There are seven 
variants of PG: ulcerative, pustular, bullous, vegetative, peristomal, genital and extracutaneous 
(Ruocco E 2009). Although the exact etiology and pathogenesis of the disease is unknown, 
as many as 70% of cases are associated with an underlying systemic disease (Crowson AN 
2003, Su WP 2004). In fact, the pustular form is the classical representation (Ruocco E 2009), 
and was first described in association with UC (O’Loughlin S 1978). New lesions occur after 
trivial trauma (Finkel SI 1981, Crownson AN 2003, Su WP 2004), and an aberrant response 
of the immune system has been implicated (Crowson AN 2003). Although only 2% of IBD 
 Cutaneous
Pyoderma gangrenosum, erythema nodosum, Stevens Johnson 
syndrome, psoriasis
 Ophtalmologic Iritis, uveitis, scleritis, episcleritis
 Musculoskeletal
Peripheral arthritis, sacroiliitis, ankylosing spondylitis , seropositive 
rheumatoid arthritis, polymyositis, osteopenia, osteoporosis
 Oral Aphtous stomatitis
 Hepatobiliary
Gallstones, autoimmune hepatitis, primary sclerosing cholangitis, 
primary biliary cirrhosis
 Hemotological
Thromboembolism, autoimmune hemolytic anemia, chronic anemia, 
chronic myeloproliferative disease, non-Hodgkin lymphoma, 
idiopathic thrombosytopenic purpura, leukopenia
 Other
Nephrolithiasis, glomerulonephritis, pancreatitis, thyreoiditis, 
systemic lupus erythematodes, Sjögren syndrome, Wegener's 
granulomatosis, asthma
 Development Growth impairment, delayed puberty
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patients suffer from PG (Callen JP 1998), IBDs account for up to 20% of the underlying 
systemic diseases (Callen JP 1998). Lesions may be noted after colectomy, or even before gas-
trointestinal disease (Cook TJ 1962, Holmlund DE 1987). Other associated diseases include 
those such as: chronic active hepatitis, myeloma, lymphoma, systemic lupus erythematosus, 
neoplasia, osteoarthris and diabetes (Ruocco E 2009, Callen JP 1998). Local, topical treat-
ments may be successful (Crowson AN 2003), but systemic immunosuppressive therapy may 
be necessary to induce remission (Ruocco E 2009, Callen JP 1998). Novel treatment with 
anti-TNF-α-agents has also been successful (Kouklakis G 2005, Juillerat P 2007). When PG 
occurs concomitantly with IBD, the skin manifestation usually responds to treatment of the 
underlying gastrointestinal disease (Ruocco E 2009). Total colectomy may also ameliorate PG 
in UC (Levitt MD 1991, Janowitz HD 1998). Removing residual rectal mucosa may also be 
necessary ( Janowitz HD 1998). 
2.5.	Matrix	Metalloproteinases	in	Inflammatory	Bowel	Diseases
2.5.1. Matrix Metalloproteinases, a Diversity of Tasks
In both UC and CD, immune factors play central roles. Dendritic cells presenting foreign 
antigens stimulate T-helper (Th) cells. Crohn’s disease acts predominantly through type 1 Th-
cells (Th1), which characteristically produce interleukin (IL)-2 and interferon-γ (Podolsky 
DK 2002, Playford RJ 2005). Macrophages are activated and secrete inflammatory cytokines 
such as TNF-α and IL-1, resulting in an inflammatory cascade where more cell types are 
stimulated, eventually leading to processes such as leucocyte recruitment (Podolsky DK 2002). 
The macrophages simultaneously promote activity of Th1-cells, creating a self-sustaining cycle 
(Podolsky DK 2002). UC is mediated by type 2 helper-T-cells, resulting in production of cy-
tokines such as IL-5 and -10 (Farrell RJ 2002, Playford RJ 2005).
In human foetal gut explant and cultured foetal small intestinal cells, T-cell activation in-
creases MMP-production, followed by matrix degradation (Pender SL 1997, Monteleone G 
1999, Salmela MT 2002). Neutralizing TNF-α inhibits MMP-production (Pender SL 1998), 
and tissue destruction is almost entirely abolished by addition of a synthetic MMP-inhibitor 
(Pender SL 1997). 
MMP production is increased in response to proinflammatory cytokines, such as IL-1ß and 
TNF-α  (Sternlicht MD 2001, Gan X 2001, Nee LE 2004). The latter can also directly dam-
age the mucosal barrier of the colon, resulting in inflammatory changes in UC (Sartor RB 
1994). Several MMPs have been recognized in processes occurring in IBD, while there are 
differences between MMP- and TIMP-expression in UC and CD. MMPs have a variety of 
actions, including ones such as recruitment of inflammatory cells, and a role in innate im-
munity (Naito Y 2005). Murine models of colitis suggest that MMPs expressed in epithelium 
may play a role in the development of the disease through the release of proteolytic activity 
(Tarlton JF 2000, Castaneda FE 2005). In dextran sulfate sodium (DSS)-induced colitis in 
mice, several MMPs are elevated, such as MMP-3, -9 and -12 (Di Sebastiano P 2001). Even 
urinary MMP levels have been proposed to serve as biomarkers for active mucosal inflam-
mation in IBD (Manfredi MA 2008). Anti-TNF-α agents have been shown to be effective 
in reducing intestinal inflammation in IBD (Kohn A 2004, Cucchiara S 2008), and MMP-
inhibitors depict similar results in animal models (Naito Y 2004). 
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Of the MMPs, MMP-9 is the most abundantly expressed MMP in IBD and correlates with 
disease activity (Baugh MD 1999). MMP-9 is expressed in stromal cells in IBD (Bailey CJ 
1994, Sternlicht MD 2001), but epithelial MMP-9 has also been shown to modulate tissue 
damage in colitis (Castaneda FE 2005). In fact, MMP-9 knockout mice have increased resist-
ance to IBD-type inflammation (Santana A 2006). In human foetal gut explants, MMP-3 
and -1 had destructive effect on mucosal organization (Pender SL 1998). Interestingly, in 
mice, MMP-3 seems to be an important factor in CD4+T lymphocyte migration into lamina 
propria (Li CK 2004). MMP-3 plays a prominent role in T-cell- and TNF-α-mediated gut 
injury (Pender SL 1997, Pender SL 1998), and is present in mucosal damaged regions in 
both UC and CD, in cells such as macrophages and fibroblasts (Bailey CJ 1994, Gunther U 
1998, Baugh MD 1999, von Lampe 2000). Stromal and epithelial expression is increased in 
inflamed CD and UC mucosa, and levels correlate with proinflammatory cytokine produc-
tion, such as TNF-α, and the histological degree of inflammation (Louis E 2000, von Lampe 
B 2000, Pedersen G 2008). However, most severe upregulation of MMP-3 occurs in ulcer-
ated inflamed intestine (von Lampe B 2000). MMP-1 staining is detected in macrophages 
in inflamed IBD tissue, but not non-inflamed tissue (von Lampe B 2000). MMP-1 is over-
expressed in macrophages in stroma of IBD mucosa (von Lampe B 2000), and like MMP-3, 
expression correlates with the histological degree of inflammation (von Lampe B 2000). It is 
important to note that the increase in MMP-1 and MMP-3 in IBD is accompanied by only 
a moderate increase in TIMP-1 (von Lampe B 2000), shifting the MMP/TIMP ratio and 
possibly creating a more protelytic environment suitable for tissue damage. In cultured hu-
man intestinal mucosal explants of both UC and CD, MMP-1, -3, and -9 are downregulated 
by anti-TNF-α-agent (Meijer MJ 2007a). In mice, MMP-7 activates cryptidins – microbial 
α-defensins – in Paneth cells of the small intestine (Wilson CL 1999). In fact, bacterial ex-
posure induces MMP-7 expression in a human colonic epithelial cell line, and MMP-7 has 
a role in activating a number of immune mechanisms (Wilson CL 1999, Lopez-Boado YS 
2000, Burke B 2004). While MMP-7 expression is upregulated in IBD and intestinal epithe-
lial cell lines (Matsuno K 2003), MMP-7 expression in healthy gut varies. Some state that 
MMP-7 is found in normal gastric mucosa, and is upregulated in gastric carcinoma (Honda 
M 1996), whereas others report that it is not found in normal small or large intestine mucosa 
(Saarialho-Kere UK 1996, Ghosh D 2002). MMP-12 is found in macrophages of inflamed 
intestine, possibly taking part in epithelial shedding (Vaalamo M 1998). Unlike expression of 
TIMP-1 and -3, that of TIMP-2 mRNA does not vary between inflamed and non-inflamed 
IBD (UC and CD) (von Lampe B 2000). TIMP-2 seems to be regulated differently than 
other MMPs and TIMPs, not wholly surprising, as TIMP-2 promoter area shares features 
found in housekeeping genes (Hammani K 1996). TIMP-2 and TIMP-3 are found in normal 
colonic epithelium, as well as in a few lamina propria mononuclear cells (Kirkegaard T 2004). 
Proposed roles and observations of MMPs in IBD are summarised in Table 4.
2.5.2. Findings in Crohn’s Disease
In CD, MMP-1 gene is upregulated in diseased areas of surgical colon specimens (Srivastava 
MD 2004), and expression of this protein is increased in CD colonic wall (Stumpf M 2005). 
Similarly, in steroid-refractory disease, lower levels of MMP-1 were able to predict long-
term remission (Schmidt C 2007). Also, a TIMP-1 single nucleotide polymorphims (SNP) is 
linked to susceptibility to CD accompanied by lower TIMP-1 protein expression in inflamed 
tissue (Meijer MJ 2007b). In addition, certain MMP-3 SNPs have been shown to associate 
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with a major risk of stenotic complications, while it may protect from colonic disease location 
(Meijer MJ 2007b). Similarly, MMP-1 is also described as profibrotic factor in CD (Warnaar 
N 2006). MMP-1 trancript levels are increased in active CD mucosa (Stallmach A 2004), and 
in CD, levels correlate strongly with clinical activity (CDAI) and with endoscopically deter-
mined disease activity (Stallmach A 2004). In addition, Crohn’s disease myofibroblasts have 
higher concentrations of TIMP-1 protein than fibroblasts of either normal colon or ulcera-
tive colitis (McKaig BC 2003). TIMP-1 could be an important factor in the development of 
strictures in CD, but not in UC (McKaig BC 2003). 
2.5.3. Findings in Ulcerative Colitis
In UC, expression of MMP-1 and MMP-7 in the inflamed mucosa correlates with the sever-
ity of disease (Wang YD 2007, Matsuno K 2003). MMP-7 is detected in mucosal epithelium 
bordering ulcerations in UC, and a higher level of matrilysin compared with a lower level of 
TIMP-1 is related to the severity of inflammation (Matsuno K 2003). Similarly, a higher 
MMP-7/TIMP-2 ratio is associated with higher Matt’s grade (severity) (Matsuno K 2003). 
MMP-1 and TIMP-1 expression in colonic mucosa of UC patients is higher than in healthy 
mucosa, also correlating with disease severity (Wang YD 2009). In an animal model of UC, 
after treatment with MMP-inhibitor ilomastat, expression of MMP-1 was decreased dose-
dependently, but TIMP-1 was not affected (Wang YD 2008), suggesting that the inhibitor 
may act by mending the MMP/TIMP balance. Interestingly, TIMP-1 in plasma might be a 
useful biomarker of the disease (Wiercinska-Drapalo A 2003). Plasma levels of both MMP-
1 and TIMP-1 are elevated compared to healthy controls (Wiercinska-Drapalo A 2003), 
but only TIMP-1 levels correlate with the severity of disease, the scored endoscopic index 
of degree of mucosal injury, clinical activity index (CAI) and disease activity index (DAI) 
(Wiercinska-Drapalo A 2003). 
2.5.4. Findings in Pouchitis
Studies on MMPs in pouchitis are scarce, but elevated levels of MMP-1 and MMP-2 tran-
script and protein are found in inflamed pouch mucosa, compared to non-inflamed pouch-
es and normal ileal mucosa (Stallmach A 2000). Increase in concentration of MMP-1 and 
MMP-2 is akin to that in active UC (Stallmach A 2000). Treatment with metronidazole 
resulted in normalized histological and clinical findings, as well as a decrease in MMP levels 
(Stallmach A 2000). Similarly, there is an increase in MMP-1 mRNA in untreated coeliac 
disease (Daum S 1999).
2.5.5. Matrix Metalloproteinases in Intestinal Wounds
Unlike in cutaneous wounds, MMP-1 is not found in epithelium bordering intestinal ulcera-
tions in IBD, but it is present in granulation tissue, in fibroblasts, in a larger number of cells 
in IBD compared to peptic ulcers of the stomach and duodenum (Saarialho-Kere UK 1996, 
Arihiro S 2001). However, in necrotizing enterocolitis ulcers, as well as in a foetal gut model 
and cultured intestinal epithelial cell lines, MMP-1 is seen in migrating enterocytes, and 
is upregulated by TNF-α in the latter (Salmela MT 2004). MMP-1 mRNA-positive eosi-
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nophils may play a part in gastric ulcer perforation (Otani Y 1997). MMP-3 is expressed in 
CD and non-CD fistulas in fibroblasts and large mononuclear cells, possibly contributing to 
fistula formation by degradation of extracellular matrix in both IBD and non-IBD processes 
(Kirkegaard T 2004). In IBD ulcer bases, MMP-3 is found in lymphocytes, possibly taking 
part in matrix degradation necessary for repair, or maintaining active inflammation (Arihiro 
S 2001, Saarialho-Kere 1996). Interestingly, while MMP-7 is generally absent in skin, it is 
found in intestinal epithelium bordering IBD and non-IBD ulcers, and in necrotizing entero-
colitis, in migrating enterocytes (Saarialho-Kere UK 1996, Salmela MT 2004). MMP-7 is not 
present in epithelium further away from the wound, or in stroma (Saarialho-Kere UK 1996), 
and expression may be influenced by degradation of basement membrane (Saarialho-Kere 
UK 1996). Interestingly, mucosal expression of MMP-7 in epithelium is induced by bacterial 
exposure, perhaps contributing to host defence through prodefensin activation (Lopez-Boado 
YS 2000), but prolonged exposure may lead to epithelial disorganization (Wroblewski LE 
2003). In humans, MMP-8 is expressed abundantly in neutrophils in ulcer bases in CD and 
UC, in a larger number of cells than in inflamed mucosa without erosions (Arihiro S 2001). 
In a mice model of IBD, MMP-8 is found in large intestine epithelium, and is suggested to 
take part in ulcer formation as well as normal homeostasis of intestinal epithelium (Pirila 
E 2003). In IBD ulcer bases, MMP-9 is found in neutrophils and macrophages (Arihiro S 
2001). However, its role in epithelial repair is not clear. While MMP-9 is expressed in corneal 
epithelial migration, a deficient amount accelerates wound healing (Mohan R 2002). In a 
murine model of colitis, MMP-9 is upregulated in epithelium, compared with wild-type mice 
(Castaneda FE 2005). Also, in an intestinal epithelial cell line, MMP-9 impairs cell adhesion 
and retards wound healing (Castaneda FE 2005). MMP-10 is expressed in the same locations 
as laminin-332, an important adhesive for migrating keratinocytes (Zhang K 1996, Vaalamo 
M 1998). Ulcers of both IBD and ischemic origin depicted MMP-10 positive migrating 
epithelial cells, as well as stromal lymphocyte- and macrophage-like cells (Vaalamo M 1998). 
MMP-10 may have a role in epithelial migration in intestine (Vaalamo M 1998). Interest-
ingly, CD fistulae are negative for this MMP, but findings in normal epithelium are contradic-
tory (Vaalamo M 1998, Kirkegaard T 2004). MMP-12 has been proposed to have a role in 
epithelial shedding and matrix degradation facilitating migration of macrophages (Vaalamo 
M 1998). TIMP-1 is found in IBD and non-IBD ulcer bases (Saarialho-Kere UK 1996), and 
TIMP-1 mRNA in expression in mucosa correlates with the severity of disease, with higher 
amount in ulcerated mucosa (von Lampe B 2000). On the other hand, TIMP-2 mRNA levels 
remain stable (von Lampe B 2000). TIMP-2 is expressed in smaller amounts in ulcer bases 
CD and UC, but abundantly in areas of active fibrosis (Arihiro S 2001). TIMP-3 is expressed 
in IBD intestine in macrophages and fibroblast-like cells in ulcer bed, as well as in normal 
intestine, although in a smaller number of cells (Vaalamo M 1998).
2.5.6 Matrix Metalloproteinases in Cutaneous Wounds
Proper wound healing requires (1) a formation of a fibrin clot and inflammatory response: 
(2) formation of granulation tissue along with re-epithelialization and angiogenesis: and (3) 
matrix formation and remodelling (Fig 4.) (Xue M 2006, Schäfer M 2008). In healthy epithe-
lium, while MMPs are not generally expressed (Parks WC 1999), MMP-2 can be extracted 
from skin (Agren MS 1994), and MMP-7 is present in exocrine glands (Saarialho-Kere UK 
1995b). In wounds, MMP-1 and MMP-10 mRNA is expressed by migrating keratinocytes 
(Vaalamo M 1996, Madlener M 1996). MMP-1 has many functions, but it seems to have a 
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role in detaching keratinocytes from the basement membrane, to enable cell migration and 
control of directionality (Pilcher BK 1997, Parks WC 1999). MMP-10 could aid keratinoc-
yte movement by degrading matrix proteins, and by removing injured basement membrane 
(Saarialho-Kere UK 1994). MMP-9 is also found in migrating keratinocytes, but to a lesser 
extent (Mirastschijski U 2002). In stroma it is found in neutrophils and macrohages in the 
ulcer bed (Mirastschijski U 2002). MMP-3 resides in keratinocytes in the proliferating zone 
behind the migrating tip, and in the dermis in fibroblasts (Saarialho-Kere UK 1994). It is 
suggested to take part in tasks such as restructuring the novel basemement membrane, and re-
moving granulation tissue (Saarialho-Kere UK 1994). In skin, interestingly, TIMP-1 mRNA 
in epithelium is found in normally healing, but not in chronic wounds (Saarialho-Kere UK 
1998, Vaalamo M 1996), suggesting that extensive proteolysis slows healing (Saarialho-Kere 
UK 1998). Similarly, the highest intensity of TIMP-1 mRNA expression in migrating and 
proliferating epithelium in burn wounds occurs during the active phase of re-epithelialization, 
colocalizing with MMP-1 mRNA (Stricklin GP 1993). TIMP-1 levels in wound fluid de-
cline as the wound becomes chronic, possibly allowing excessive protelysis (Nwomeh BC 
1999). In chronic wounds, increased expression of TIMP-2 by fibroblasts is associated with 
impaired ability to reorganize extracellular matrix (Cook H 2000). Oral mucosal fibroblasts 
express less TIMP-2 than their cutaneous counterparts, which could account for the more 
rapid re-epithelialization of oral mucosal wounds (Stephens P 2001). In vitro, however, add-
ing TIMP-2 to human epidermal keratinocytes increases their migratory potential, and in 
rodents, results in faster cutaneous wound closure (Terasaki K 2003). Levels of active MMP-8 
in chronic wound fluid are elevated, and may reflect the severity of neutrophil infiltrations in 
these wounds (Nwomeh BC 1999). MMP-2 is not present in wound epithelium, but is found 
in stroma in fibroblasts (Mirastschijski U 2002).
Figure 4. Phases of cutaneous wound healing: a.) inflammatory phase and formation of fibrin 
clot, b.) formation of granulation tissue, angiogenesis and re-epithelialization, c.) tissue re-
modelling. Adapted by the permission from Macmillan Publishers Ltd: Nature Reviews Molecular 
Cell Biology (Schäfer M 2008), copyright (2008).
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Table 4. Proposed functions and observations of MMPs in IBD.
CD UC
 MMP-1
Correlation with disease activity,
Prediction of long-term remission,
Fistula formation,
Stromal remodelling
Correlation with disease severity,
Stromal remodelling
 MMP-3
Mucosal damage,
Correlation with degree of inflammation, 
Stricture formation,
Fistula formation
Mucosal damage,
Correlation with degree of inflammation
 MMP-7
Migration and proliferation of epithelial 
cells / epithelial remodelling
Migration and proliferation of epithelial 
cells / epithelial remodelling, Correlation 
with disease severity,
Malignant transformation
 MMP-8 Ulcer formation (studies in mice) Ulcer formation (studies in mice)
 MMP-9
Tissue damage,
Fistula formation
(protection from disease recurrence)
Tissue damage,
Correlation with disease activity
 MMP-10
Migration of epithelial cells,
Intestinal re-epithelialization 
Migration of epithelial cells,
Intestinal re-epithelialization 
 MMP-12
Macrophage migration,
Epithelial cell shedding
Macrophage migration,
Epithelial cell shedding
 MMP-26
Cleavage of integrins
(underneath epithelium, in
basement membrane area)
Epithelial cell migration, Cleavage of 
integrins (underneath epithelium, in 
basement membrane area)
 TIMP-1
MMP-inhibition,
Protection from disease recurrence,
Correlation with disease activity,
Stricture development
MMP-inhibition,
Correlation with disease severity,
Disease biomarker
 TIMP-2
MMP-inhibition,
Protection from disease recurrence
MMP-inhibition,
Constitutively expressed
 TIMP-3
MMP-inhibition,
Targeted extracellular matrix 
degradation, Protective/damaging effect 
on epithelium
MMP-inhibition,
Targeted extracellular matrix 
degradation
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3. Aims of the Study
Matrix metalloproteinases have been demonstrated in a variety of processes, both physi-
ological and pathological. They have been linked to intestinal inflammation and injury, re-
epithelialization in both intestine and skin, as well as colorectal cancer. In this thesis, the aim 
was to further establish characteristics of IBD inflammation.
Specific	objectives:
I To investigate intestinal mucosa of CD patients receiving either anti-TNF-α-
 agents or corticosteroids and conventional immunosupressants, and to identify 
 possible therapeutic targets for selective MMP-inhibition.
II To examine colonic samples of paediatric UC and CD patients, and to find tools
 to aid in differentiating between the two disorders. Also, to examine differences
 between colonic mucosa of non-IBD patients and of patients with IBD.
III To examine the MMP- and TIMP-profiles in pouch intestinal mucosa of UC
 patients who underwent proctocolectomy at childhood or adolescence, and to
 investigate the type of inflammation in the pouch. 
IV To investigate pyoderma gangrenosum, an extraintestinal manifestation of inflam-
 matory bowel disease, and to compare its MMP- and TIMP-profile with that of
 IBD and normally healing wounds.
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4. Materials and Methods
4.1.	Tissue	Samples
The studies were approved by the Ethics Committee of the Department of Medicine, Univer-
sity of Helsinki, Helsinki University Central Hospital (I, III, IV), and by the National Super-
visory Authority for Welfare and Health (II). In each study, samples were formalin-fixed and 
paraffin embedded. As negative controls, parallel sections of the same samples were processed 
using preimmune sera or normal rabbit or mouse immunoglobulin. The positive controls used 
were sections of hailey-hailey, pyoderma gangerosum and dermatitis herpetiformes (MMP-
3), squamous cell cancers (MMP-1, MMP-8 and -10), adenocarcinoma (MMP-7), chronic 
wounds (LN-5, MMP-8 and -9, and TIMP-1, -2 and -3), foreign body reaction (MMP-12), 
pyoderma gangrenosum (TIMP-1), endometrium (MMP-26), and chronic wounds (TNF-α). 
In study IV, normally healing wounds from the upper thigh were used as internal controls.
I   Crohn’s disease
Seventeen CD patients referred for ileocolonoscopy were recruited between January 2005 and 
June 2007 at the Helsinki University Central Hospital, Helsinki, Finland. Of these, 7 were 
male, 10 female (ages 19-47 years, mean 26.5 yrs). The duration of disease ranged between 
0-249 months (mean 75 mo.), with one patient newly diagnosed. Samples were taken from the 
segment of colon most affected (according to the Scoring System for Histological Abnormali-
ties in Crohn´s Disease Mucosal Biopsy Specimens, D’haens GR 1998, Table 5.) during the 
baseline endoscopy (5 right colon, 6 transverse, and 6 left colon). Post-treatment samples were 
obtained during endoscopy, 3 months after the baseline endoscopy in anti-TNF-alpha-treated 
patients (n=12), and after 4-6 months in patients who received conventional immunosuppres-
sive treatment (methotrexate or azathioprine) (n=5).
II  Paediatric IBD in the colon
Between May 2005 and February 2007, we retrieved samples from 32 patients with pancolitis 
from the pathology files of the Central Pathology Laboratory of Helsinki University Hospital. 
The diagnoses included CD (n=11), UC (n=12), IC (n=4), and also UC with diagnosis being 
redefined as CD after follow-up (n=5). All samples were from the descending colon. Seven-
teen patients were female and 15 male, ages ranging between 2.7 and 18 years (mean 12 yrs.). 
The control group comprised 11 patients without IBD, ages ranging between 2.5 and 13.9 
years old (mean 9.1 yrs.), and all but one were devoid of colitis. 
III Pouchitis
Proctocolectomy was performed on 81 paediatric UC patients between 1985 and 2005 at 
Tampere University Hospital or the Hospital for Children and Adolescents, Helsinki. Seven-
tenty-nine of these patients were traced from the database of the Population Register Centre 
and contacted by mail during 2006, and 35 patients agreed to participate in a follow-up visit. 
Seven patients had been rediagnosed as having CD. During the follow-up visit, a biopsy from 
the pouch was obtained. The histological grade of inflammation in the samples was assessed 
according to the scoring system for pathological changes in the ileal reservoir mucosa (Shep-
herd NA 1987, Pakarinen MP 2010) (Table 6.).
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IV Pyoderma gangrenosum
Archival specimens of 22 PG patients (24 samples altogether) were obtained from the De-
partment of Dermatology, University of Helsinki, Finland. The PG samples represented vari-
ous types: bullous (n=2), pustular (n=3), vegetative (n=9), ulcerative (n=5) and vesicopustular 
(n=4). Five PG patients had underlying IBD: UC (n=2) and CD (n=3). Of the patients, 12 
were female, 10 male, with a median age of 52 years, ranging between 13 and 82 yrs. Biopsies 
had been taken before starting systemic treatment for PG. In addition, four timed (1, 2, 3 and 
4 days old) normally healing wounds from the upper thigh were examined (Vaalamo M 1996).
4.2.	Inflammation	Indicators
Faecal calprotectin (study I, II, III) was measured using a quantitative enzyme immunoessay 
(PhiCal Test, Calpro AS, Oslo, Norway; NovaTec Immunodiagnostica, Dietzenbach, GmBH, 
Germany). Blood biomarkers of inflammation (erythrocyte sedimentation rate [ESR] and 
serum concentration of C-reactive protein [CRP]) (study I, II, III) were determined routinely. 
Findings in endoscopy (study I) were scored according to Crohn´s Disease Index of Severity 
(CDEIS) (Mary JY 1989) and clinical activity according to Crohn´s Disease Activity Index 
(CDAI) (Best WR 1976).
Table 5. Scoring system for Histological abnormalities in Crohn’s Disease Mucosal Biopsy 
Specimens (study I) (Modified from D’Haens GR 1998)
 
Feature Score
0, Normal
1, Focal pathology
2, Extensive pathology
0, Normal
1, Moderately disturbed (<50%)
2, Severely disturbed (>50%)
0, Normal
1, Moderate  increase
2, Severe increase
0, Normal
1, Moderate increase
2, Severe increase
1, In surface epithelium
2, Cryptitis
3, Crypt abscess
0, No
1, Yes
0, No
1, Yes
0, None (0 of 6)
1, ≤33% (1 or 2 of 6)
2, 33-66% (3 or 4 of 6)
3, >66% (5 or 6 of 6)
Presence of granuloma
No. of biopsy specimens affected
Architectural changes
Epithelial damage
Infiltration of mononuclear cells in the lamina propria
Infiltration of polymorphonuclear cells in the lamina 
propria
Polymorphonuclear cells in epithelium
Presence of erosion and/or ulcers
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Table 6. Scoring system for histopathological changes in reservoir mucosa (study III) (Modi-
fied from Shepherd NA 1987)
 
4.3.	Immunohistochemistry
Immunohistochemistry was performed using streptavidin-biotin-peroxidase complex tech-
nique (DakoCytomation, StreptABComplex/HRP Duet, Mouse/Rabbit, Glostrup, Den-
mark; and Elite Goat IgG Vectastain ABC kit, Vector laboratories, Burlingame, CA, USA) or 
the antibody-polymer detection technique (Dakocytomation, Envision + Dual Link System-
HRP; and ImPRESS Universal Reagent, Mouse/Rabbit, Vector laboratories). Diaminoben-
zidine (DAB), 3-Amino-9-ethylcarbazole (AEC) and NovaRED (Vector Laboratories) were 
used as chromogenic substrates and Mayer’s haematoxylin as counterstain. After deparaffin-
izing and rehydrating the samples, they were treated with 3% hydrogen peroxide to block 
endogenous peroxidase activity. Then, samples were pretreated – when necessary – with either 
1% trypsin solution for 30 minutes at room temperature or +37˚C, or with +95˚C water bath 
in a citrate buffer solution (Dakocytomation) for 20-30 minutes (Table 7.). 
Histological feature Score
Acute
Polymorph infiltration
   None 0
   Mild and patchy infiltrate in the surface epithelium 1
   Moderate with crypt abscesses 2
   Severe with crypt abscesses 3
Ul icerat on
   None 0
   Mild superficial 1
   Moderate 2
   Severe 3
Chronic
Chronic inflammatory cell infiltrate
None 0
   Mild and patchy 1
   Moderate 2
   Severe 3
Villous atrophy
   None 0
   Minor abnormality of villous architecture 1
   Partial villous atrophy 2
   Subtotal villous atrophy 3
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In study IV, immunohistochemical specimens were graded in a semiquantitative manner un-
der a light-field microscope at x 100 magnification using a scale marking staining intensity 
as follows: 0 = less than 10 positive cells; 1 = 10-20 positive cells; 2 = 20-50 positive cells; 3 = 
over 50 positive cells. In studies I-III, the scale was as follows: 0 = less than 20 positive cells; 1 
= 20-50/100 positive cells; 2 = 50/100-200 positive cells; 3 = over 200 positive cells.
4.4.	Statistics
Statistical analysis was performed using paired and independent samples t-tests (I, IV), non-
parametric Wilcox (I) and non-parametric Mann-Whitney’s (I, II, III) and Spearman’s cor-
relation tests (I, II, III) to investigate the significance of results with the Statistical Package 
for Social Sciences (SPSS) 15.0 & 17.0 for Windows.  A p value under 0.05 was considered 
significant.
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Table 7. Specifications of antibodies used.
A
ntibody
clone/
catalogue #
Source
D
ilution
A
ntibody incubation
pretreatm
ent
Study
M
M
P
-1
IM
35L
O
ncogene R
esearch P
roducts, L
a Jolla, C
A
 U
S
A
1:500-600
+
4˚C
 overnight
1%
 trypsin or +
95˚C
 w
ater bath in citrate buffer solution 
I,II,IV
M
M
P
-3
ab32607
A
bcam
 ltd, C
am
bridge, U
K
1:50
1h at R
T
+
95˚C
 w
ater bath in citrate buffer solution
III
M
M
P
-7
IM
40L
C
albiochem
1:100-130
+
4˚C
 overnight
+
95˚C
 w
ater bath in citrate buffer solution
I,IV
M
A
B
3315
C
hem
icon, T
em
ecula, C
A
, U
S
A
1:600
+
4˚C
 overnight
+
95˚C
 w
ater bath in citrate buffer solution
II,III
M
M
P
-8
IM
38L
C
albiochem
1:20
1½
h at +
37˚C
1%
 trypsin solution
IV
IM
38
C
albiochem
1:200
1½
h at +
37˚C
1%
 trypsin solution
II,III
M
M
P
-9
G
E
-213
R
D
I, F
landers, N
J, U
S
A
1:50
1½
h at +
37˚C
1%
 trypsin solution
IV
M
S
-569-P
1
N
eom
arkers, F
rem
ont, C
A
, U
S
A
1:100
+
4˚C
 overnight
1%
 trypsin solution
I-III
M
M
P
-10
N
C
L
-M
M
P
-10
N
ovocastra laboratories, N
ew
 C
aste upon T
yne, U
K
1:300
2h at R
T
1%
 trypsin solution
IV
5E
4
N
ovocastra laboratories
1:250-300
+
4˚C
 overnight or 2h 
at R
T
1%
 trypsin solution
I,II
M
M
P
-12
sc-12361
S
anta C
ruz B
iotechnology, C
A
, U
S
A
1:80
+
4˚C
 overnight
none
II,III
M
M
P
-26
P
rof. K
eiichi Isaka, T
okyo M
edical U
niversity
1:120-150
1h at R
T
 or +
37˚C
+
95˚C
 w
ater bath in citrate buffer solution
I-IV
T
IM
P
-1
IM
63
C
albiochem
1:50-100
+
4˚C
 overnight
+
95˚C
 w
ater bath in citrate buffer solution
I-IV
T
IM
P
-2
IM
56
C
albiochem
1:600
+
4˚C
 overnight
+
95˚C
 w
ater bath in citrate buffer solution
III
T
IM
P
-3
IM
43L
C
albiochem
1:400
+
4˚C
 overnight
+
95˚C
 w
ater bath in citrate buffer solution
I-IV
T
N
F
-α
ab9579-100
A
bcam
 ltd
1:50
+
4˚C
 overnight
1%
 trypsin solution
IV
L
N
-5
P
rof. K
arl T
ryggvason, K
arolinska Institute, S
w
eden
1:700
+
4˚C
 overnight
1%
 trypsin solution
IV
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5. Results and Discussion
5.1.	MMPs	and	TIMPs	in	adult	Crohn’s	Disease
Anti-TNF-α agents and corticosteroids along with other immunosuppressive treatment are 
effective against CD. Although we know their actions in part, such as inhibition of the proin-
flammatory cytokine TNF-α, we are not aware of the final steps in healing intestinal mucosa. 
Here, MMP and TIMP profiles were assessed in adult patients with moderate to severe CD 
before and after immunosuppressive treatment with either anti-TNF-α agents (n=12), or with 
corticosteroids and conventional immunosuppressants (n=5). The findings are summarised in 
figure 5, and tables 8 and 10. 
5.1.1. Neutrophil MMP-9 and -26 respond to immunosuppressive therapy
MMP-9
In epithelium, MMP-9 was generally absent from all samples: only one sample taken three 
months after therapy depicted MMP-9 positive epithelium. Stromal expression was present in 
neutrophils in 16/17 of pre-treatment samples and in 12/17 post-treatment samples. Positive 
macrophages were present in 14/17 pre-treatment and 12/17 post-treatment samples. While 
macrophageal expression of MMP-9 did not show statistical differences between pre-treat-
ment and post-treatment samples, there was a significantly higher number of MMP-9 posi-
tive neutrophils in initial samples (2.12 vs. 1.29, p=0.039). Also, a higher number of positive 
neutrophils were found in samples that were considered active according to CRP (≥10 mg/l), 
and a similar trend was present with Crohn’s disease endoscopic index of severity (CDEIS >9) 
(2.27 vs. 1.43, p=0.020; 2.00 vs. 1.38, p=0.061, respectively). Surprisingly, both neutrophil and 
macrophage MMP-9 showed positive correlation with mucosal inflammation, as assessed by 
the scoring system for histological abnormalities in CD mucosal biopsy specimens (D’Haens 
GR 1998) (corr.coeff. 0.577, p<0.000; corr.coeff. 0.439, p=0.009 respectively).
MMP-9 is generously expressed MMP in IBD (Bailey CJ 1994, Baugh MD 1999). MMP-9 
null mice are not susceptible to an induced state of colitis (Castaneda FE 2005), while the 
MMP is upregulated in intestinal inflammation (Castaneda FE 2005). MMP-9 expression in 
CD has been shown especially in polymorphonuclear cells (Bailey CJ 1994, Gao Q 2007), but 
in a mouse model of colitis, in epithelial cells as well (Castaneda FE 2005). Some speculate 
that MMP-9 participates in oral mucosal wound healing, in keratinocyte migration and tis-
sue remodelling (Salo T 1994), but decreased expression in mice results in accelerated wound 
healing (Mohan R 2002). Accordingly, in a cultured intestinal epithelial cell line, MMP-9 
impairs wound closure by effecting cell adhesion (Castaneda FE 2005). Neutralization of 
TNF-α downregulates endotoxin-related release of MMP-9 in blood (Pugin J 1999). Also, 
anti-TNF-α-agent, infliximab, has been shown to decrease serum levels of MMP-9 and the 
number of MMP-9 positive polymorphonuclear cells (Gao Q 2007). The present results agree 
with this, as shown by decreased numbers of MMP-9 positive neutrophils after treatment, and 
positive correlation with inflammation indicators. Thus, one mechanism through which anti-
TNF-α agents and conventional immunosuppressant act, could be the reduction of MMP-9 
in CD mucosa. However, MMP and TIMP profiles in both UC and CD share similarities, 
and MMP-9 expression has been demonstrated in other conditions such as necrotizing en-
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terocolitis (NEC) (Bister V 2005a). NEC resembles IBD in that it also portrays increased 
TNF-α levels (Pender SL 2003). It is proposed that injury to the intestine is necessary to 
upregulate MMP-9, and this protein is not found in a rat model of obstructed colon nor is 
mRNA in human diverticulosis (Syk I 2003, Mimura T 2004). MMP-9 digests a variety of 
ECM molecules such as gelatin, laminin and type IV and V collagen (Egeblad M 2002), and 
appears as pivotal in inflammation and tissue destruction (Baugh MD 1999, Tarlton JF 2000). 
This, together with the present findings, suggest MMP-9 to be an important pathological 
MMP in CD inflammation, and an attractive target for possible future MMP-inhibitors in 
treating CD. MMP-9 inhibition in other gut disorders, such as UC or NEC, may also prove 
beneficial in the future.
MMP-26
MMP-26 was lacking in the surface epithelium of all samples. In stroma, endothelial cells and 
neutrophils showed positivity. In pre-treatment samples, 15/17 samples had positive stromal 
expression, versus 7/17 post-treatment samples. MMP-26 expression in neutrophils decreased 
with treatment (0.94 vs. 0.53, p=0.030). Similarly, biopsies representing active disease (faecal 
calprotectin ≥200 ug/g or CDEIS>9) depicted greater expression of neutrophil MMP-26 
than samples considered inactive (0.91 vs. 0.36, p=0.013; 0.94 vs. 0.50, p=0.017 respective-
ly).  There was also strong positive correlation between MMP-26 expression in neutrophils 
and histological score (D’Haens GR 1998), as well as faecal calprotectin (corr.coeff. 0.418, 
p=0.014; corr.coeff. 0.432, p=0.011 respectively).
MMP-26 protein in the intestine was demonstrated earlier in polymorphonuclear leuco-
cytes (Li W 2004), epithelium, macrophages, and endothelial cells (Bister V 2005a,b). While 
MMP-26-positive migrating epithelial cells can be found in UC, they are not seen in CD 
(Bister VO 2004), and our group has previously suggested that MMP-26 is not involved in 
destructive changes occurring in IBD (Bister VO 2004). However, this study demonstrates 
MMP-26 expression in CD, responsive to immunosuppressive treatment. As with MMP-9, 
therapeutic agents (anti-TNF-α agents and conventional immunosuppressants) seem to exert 
part of their effect by downregulating MMP-26 positive neutrophils. It is worth noting that, 
as in IBD, TNF-α transcripts are elevated in NEC (Pender SL 2003), and stromal expres-
sion of MMP-26 protein is upregulated as well (Bister V 2005a). Similarly, in coeliac disease, 
stromal MMP-26 in mucosa is present in a higher number of cells when higher titers of anti-
tissue transglutaminase are present (Bister V 2005b). The damaging actions of MMP-26 in 
IBD mucosa may be due to its ability to activate pro-MMP-9 (Uria JA 2000, Zhao YG 2003) 
and degrade several matrix and basement membrane proteins (Uria JA 2000, Park HI 2000). 
MMP-26 has been proposed to be involved in the severe damage in necrotic tumour tissue 
(Marchenko GN 2001). This presents MMP-26 as a very potent MMP in CD tissue injury, 
and as shown here, mucosal healing associates with MMP-26 downregulation. While epithe-
lial MMP-26 has been associated with wound healing (Ahokas K 2005), specific inhibition 
of stromal MMP-26 could be therapeutic in CD. It is worth noting that MMP-26 is found 
around cancer cell islets in the matrix in colorectal carcinoma (Bister VO 2004). The role of 
MMP-26 in neoplasms is unclear. The lack of MMP-26 has been proposed to be a marker 
of aggressive tumour growth in skin (Ahokas K 2005), while in immunosuppressed patients 
an opposite role is suggested (Kuivanen T 2009). In esofagal carcinoma, MMP-26 correlates 
with tumour invasion and metastasis (Yamamoto H 2004). We do not know what the effect 
of residual MMP-26 in treated CD patients is, and it would be interesting to examine for 
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example, whether these patients have an increased risk of carcinoma. In either case, MMP-26 
in stroma could be a potential target for MMP-inhibitors to aid in mucosal healing of CD.
5.1.2. Immunosuppressive treatment downregulates stromal TIMP-1 and  
TIMP-3, but upregulates epithelial TIMP-3
TIMP-1
Epithelial expression of TIMP-1 was found in 8/17 samples pre-treatment, and 5/17 samples 
post-treatment, with no significant differences between the two groups. Stromal expression 
of TIMP-1 was found in 14/17 samples and 8/17 samples respectively. Both neutrophil and 
macrophage expression was greater in samples before treatment (0.47 vs. 0, p=0.041; 1.76 vs. 
0.76, p=0.003 respectively). However, macrophage expression showed stronger positive corre-
lation with indicators of inflammation; faecal calprotectin, CDEIS and total histological score 
(corr.coeff. 0.586, p<0.000; corr.coeff. 0.451, p=0.007; corr.coeff. 0.524, p=0.001 respectively). 
Similarly, biopsies considered active according to CDEIS (>9) and faecal calprotectin (≥200 
ug/g) depicted stronger stromal macrophage expression (1.78 vs. 0.69, p=0.002; 1.61 vs. 0.55, 
p=0.005 respectively). TIMP-1 in neutrophils was present in a higher number of cells in sam-
ples considered active according to CDEIS (0.44 vs. 0, p=0.046).
Previously, an overproduction of MMPs in comparison with TIMPs has been presented in 
IBD (Louis E 2000, Matsuno K 2003). In both IBD and non-IBD ulcer bases, TIMP-1 
mRNA is present (Saarialho-Kere UK 1996), and expression in mucosa correlates with the 
severity of disease, depicting higher amount in ulcerated mucosa (von Lampe B 2000). Ele-
vated TIMP-1 mRNA is also found in coeliac disease (Ciccocioppo R 2005), in macrophages, 
fibroblasts and myofibroblasts (Daum S 1999). In a mice model of colitis, TIMP-mRNA was 
upregulated (Naito Y 2004), while in a T-cell mediated tissue injury in foetal gut explants, 
TIMP-1 mRNA is downregulated after T-cell activation (Salmela MT 2002), possibly re-
flecting an imbalance between protease and inhibitors, favouring tissue injury. Intriguingly, in 
rheumatoid arthiritis, TIMP-1 serum levels correlate with markers of disease activity (Klim-
iuk PA 2004). Levels decrease with anti-TNF-α-agents, still correlating with the activity of 
disease (Klimiuk PA 2004). Also, TIMP-1 does present as an important player in the gut, as in 
colorectal cancer, plasma levels are increased (Waas ET 2005, Holten-Andersen MN 2002), 
and higher expression correlates with shorter survival (Waas ET 2005). Earlier studies also 
suggest TIMP-1 to associate with CD activity, as serum levels of TIMP-1 have been noted to 
be highest in patients with severe disease activity (Holten-Andersen MN 2002), and plasma 
levels in UC patients correlate with clinical and mucosal severity of disease (Wiercinska-
Drapalo A 2003). These findings are in line with this study. Here it is shown that both stromal 
macrophage and neutrophil expression of TIMP-1 decreased with immunosuppressive treat-
ment, although macrophage expression correlated with more inflammation indicators. TIMPs 
in this study would be expected to have therapeutic effects, as they are capable of inhibiting 
actions of MMP. Possibly the decrease in TIMP-1 here in fact reflects a decrease in MMP-
levels. It may be that the initial surplus of TIMP-1 in pre-treatment samples was effectively 
trying to neutralize MMPs present in excess. In culture, infliximab and recombinant TIMP-1 
enchance Crohn’s disease myofibroblast migration, promoting wound healing (Di Sabatino 
A 2007). TIMP-1 could also be expected to have a protective role in IBD, as it can inhibit 
neutrophil migration (Delclaux C 1996). As such, despite the decrease in TIMP-1 along with 
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treatment, it is not suggested that TIMP-1 inhibitors would automatically have a beneficial 
effect in treating CD. Rather, the abundance of stromal TIMP-1 expression is a result of 
pathological processes ongoing in the gut, not a direct cause.
TIMP-3
Epithelial TIMP-3 was detected in 13/17 samples pre-treatment, 16 samples post-treatment. 
Stromal expression was present in all samples, in macrophages and plasma cells. While epithe-
lial findings depicted a trend for stronger expression in post-treatment samples (1.18 vs. 1.71, 
p=0.058), stromal expression was stronger in pre-treatment samples (2.65 vs. 2.29; p=0.029). 
Epithelial TIMP-3 also presented an inverse assocation with CDEIS and CRP (corr. co-
eff. -0.462, p=0.006, and corr. coeff. -0.486, p=0.004 respectively), while similar trends were 
present for faecal calprotectin (corr. coeff. -0.335, p=0.053). Stromal TIMP-3, on the other 
hand, presented with positive correlations with faecal calprotectin and CDEIS (corr. coeff. 
0.541, p=0.001, and corr. coeff. 0.469, p=0.005, respectively). Expression in stroma was also 
higher in samples considered active for CDEIS or faecal calprotectin (2.67 vs. 2.25, p=0.014, 
and 2.61 vs. 2.18, p=0.019 respectively). 
In inflamed intestine, such as IBD or ischemic bowel disease, expression of TIMP-3 mRNA 
is found in cells such as macrophage- and fibroblast-like cells, and expression is upregulated 
(Vaalamo M 1998). The present finding of elevated stromal expression in CD before treat-
ment is in line with these earlier findings. Like TIMP-1, TIMP-3 is capable of inhibiting 
several MMPs, such as MMP-9 (Egeblad M 2002). TIMP-3 is expressed abundantly in ulcer 
stroma, suggesting that tissue inhibitors of metalloproteinases act to achieve targeted ECM 
degradation (Vaalamo M 1998). Lack of TIMP-3 is generally associated with enhanced pro-
teolysis, maladaptive matrix remodelling and tissue injury (Tian H 2007, Mohammed FF 
2004, Fedak PW 2004, Gill SE 2009). Abundant stromal expression of TIMP-3 is also seen in 
chronic cutaneous ulcers, suggestive of an altered MMP/TIMP-balance (Vaalamo M 1999). 
Interestingly, reduced plasma TIMP-3 activity has been reported in CD, irrespective of clini-
cal disease activity (Kossakowska AE 1999). This is an interesting finding and unlike that of 
TIMP-1 in IBD (Holten-Andersen MN 2002). TIMP-3 can also inhibit TNF-α converting 
enzyme (TACE) (Amour A 1998), and in this way reduce the level of soluble TNF-α in mu-
cosa, an important mediator of inflammation in IBD (Plevy SE 1997, Olsen T 2009). Plasma 
activity levels in CD possibly represent an overall lack of TIMP-3 in IBD, reflecting a state 
of inflammation. Elevated TIMP-3 in stroma of IBD mucosa may be an effort to counteract 
the excessive proteolysis by MMPs, and – as suggestested for TIMP-1 – is actually the result 
of upregulation of MMPs. 
Results here associate increased epithelial TIMP-3 expression with less disease activity in 
CD. TIMP-3 in epithelium has been linked to protective effects. In TIMP-3 deficient mice, 
mammary glands show extensive epithelial shedding and apoptosis (Fata JE 2001). In the co-
lon, TIMP-3 protein is reported in normal epithelium, whereas it is found in stroma in colon 
carcinoma (Zeng Z 2001). Zeng et al (2001) describe TIMP-3 to be a BM-associated protein, 
and suggest it to have a role in preventing proteolytic degradation. Indeed, in cutaneous ulcers, 
TIMP-3 is proposed to stabilize newly formed BM, although it is found in both chronic and 
acute wounds (Vaalamo M 1999). TIMP-3 inhibits TACE activity in vivo, which can process 
TNF-α precursor into the soluble active form, in this way controlling levels of TNF-α and 
also inflammation (Black RA 2002, Mohammed FF 2004). TACE protein is expressed in 
normal human colonic mucosa, in epithelium and stromal cells, and activity is increased in ac-
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tive IBD, although results are contradicting for CD (Fogh P 1999, Brynskov J 2002). In vitro, 
migration of polymorphonuclear leucocytes (PMNL) across epithelium induces TNF-α and 
IL-1ß secretion by an intestinal epithelial cell line (Betis F 2003), and upregulates TACE in 
human colonic epithelial cells (Cesaro A 2009). However, while Cesaro et al (2009) report 
increased TACE expression in inflamed intestinal epithelium of CD patients, TIMP-3 is not 
elevated, and stronger staining for TIMP-3 in epithelium is found in a quiescent phase of CD. 
Indeed, in vitro, TACE inhibition sensitizes intestinal epithelium to TNF-α, and amplifies 
TNF-α mediated intestinal epithelial barrier dysfunction (Freour T 2009). So, while colonic 
epithelium has been suggested to be a specific target for drugs aimed at inhibiting TNF-α 
processing (Kirkegaard T 2004), there may be severe limitations. The lack of expression of 
TIMP-3 in epithelium in active CD may prevent further damage to the intestinal epithelium. 
Results here suggest that greater epithelial expression seems to characterize less active disease. 
The association of epithelial TIMP-3 with lower disease activity puts forth a role in intestinal 
epithelial regeneration, but the effect of TIMP-3 may be much more complex. It is possible 
that epithelial TIMP-3 in active CD is downregulated as an act of self-preservation. In that 
scenario, it is possible that the epithelium in active disease simultaneously loses a part of its 
regenerative and preservative capabilities, perhaps to prevent more serious damage.
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Figure 5. Relative expression of M
M
P-9, M
M
P-26, TIM
P-1 and TIM
P-3 in pre- and post-treatment samples of adult Crohn’s patients, expressed 
as percentage of samples.
Nf, stromal neutrophils; mf, stromal macrophages; pre-treatment/blue columns, at baseline endoscopy; post-treatment/red columns, after treatment 
with either anti-TNF-α-agent or conventional immunosuppressant;  0 = less than 20 positive cells in sample; 1= 20-50 positive cells; 2 = 50-100 
positive cells; 3 = over 200 positive cells. 
63
5.2.	Differential	diagnosis	in	paediatric	colitis	of	IBD-origin
In paediatric IBD, differential diagnosis is challenging. Inflammation repeatedly presents only 
in the colon, and may have features of both UC and CD. Indeed, a number of children suffer-
ing from IBD cannot be characterized as having clearly UC or CD. In several cases, the in-
flammation is indeterminate, and termed indeterminate colitis (Griffiths AM 2000). Patients 
may also be rediagnosed during follow-up, shifting between the diagnosis of UC, CD or IC 
(Turunen P 2009). We aimed to examine mucosal MMP and TIMP profiles in paediatric 
colonic inflammation, and to find if differences – or similarities – between the different types 
IBD-disorders or non-IBD inflammation exist. The findings are summarised in figure 6, and 
tables 8 and 10. 
5.2.1. Epithelial MMP-10 and stromal TIMP-3 are upregulated in IBD
MMP-10
In paediatric patients, epithelial MMP-10 was elevated in both CD and UC versus non-
IBD samples (1.55 vs. 1.00, p=0.041; 1.58 vs. 1.00, p=0.025 respectively). There were no sig-
nificant differences between epithelial expression in samples with other diagnoses. Expression 
of MMP-10 in epithelium correlated positively with faecal calprotectin (corr. coeff. 0.397, 
p=0.030) and CRP (corr. coeff. 0.450, p=0.009). There were no significant differences between 
expression in stroma between the different diagnoses. MMP-10 positive plasma cells were 
present in all IBD-sample groups, whereas MMP-10 positive neutrophils were only seen in 
CD, UC and “false UC”, that is, UC samples that were rediagnosed as CD during follow-up. 
Germinal centres depicted positivity in CD, UC and non-IBD groups.
In skin, MMP-10 colocalizes with laminin-332 produced by migrating cells (Zhang K 1996, 
Rechardt O 2000), and MMP-1 mRNA (Saarialho-Kere UK 1994, Vaalamo M 1996). Inter-
estingly, MMP-10 is also found in PG epithelium (study IV), but in other cutaneous wounds 
as well (Saarialho-Kere UK 1994, Vaalamo M 1996). Our group earlier demonstrated MMP-
10 mRNA in enterocytes bordering IBD ulcers, but it is not found in intact intestinal epithe-
lium (Vaalamo M 1998, Newell KJ 1994). MMP-10 mRNA, like MMP-1 and -7 mRNA, is 
present in migrating enterocytes in intestinal ulcers (Salmela MT 2004). In a mice model of 
colitis and in cultured intestinal epithelial cells, MMP-10 mRNA is upregulated by cytokines 
important in wound repair, and MMP-10 takes part in intestinal re-epithelialization (Salmela 
MT 2004). Thus, the findings of MMP-10 expression in paediatric IBD epithelium seem to 
be in line with earlier reports. It seems logical that MMP-10 expression is upregulated in dis-
orders where TNF-α is elevated, such as in IBD (Shih DQ 2008, Olsen T 2009). MMP-10 
may aid re-epithelialization by removing damaged basement membrane and degrading matrix 
components (Saarialho-Kere UK 1994). It is also capable of activating MMP-1 (Nagase H 
1998), which keratinocyte migration is dependent upon (Pilcher BK 1997). Although MMP-
10 mRNA is not found in stroma of intact colon (Vaalamo M 1998), the non-IBD paediatric 
patients here had indications for endoscopy. It is thus unclear if their intestinal mucosa is 
completely healthy. While stromal expression of MMP-10 in intestine was similar in IBD and 
non-IBD colon, it is interesting that, along with other cytokines, KGF-mRNA and protein 
is upregulated in UC and CD intestine, and has been implicated in intestinal epithelial repair 
(Brauchle M 1996). While KGF mRNA and protein is not found in inflammatory cells, it is 
expressed by mesechymal cells in close proximity to PMNL and macrophages (Brauchle M 
64
1996), suggesting a link between the two. This may in part explain why MMP-10 positive 
neutrophils were only found in CD, UC and false UC samples. It is proposed that increased 
MMP-10 expression in colonic epithelium is suggestive of IBD-type inflammation, and may 
be used to aid diagnosis. Similarly, if MMP-10 positive neutrophils are found, these could 
support diagnosis of either UC or CD.
TIMP-3
TIMP-3 expression in stroma is increased in CD and UC versus non-IBD samples (2.18 
vs. 1.36, p=0.026; 2.50 vs. 1.36, p=0.002 respectively). Stromal TIMP-3 also correlated posi-
tively with faecal calprotectin (corr. coeff. 0.388, p=0.034). Expression in stroma was present 
in plasma cells in all sample groups. Germinal centres were positive in only CD and non-IBD 
groups. TIMP-3 positive epithelium was found in all sample groups.
In study I, increased stromal TIMP-3 is shown in CD samples before treatment. Earlier it was 
reported that TIMP-3 mRNA is upregulated in IBD ulcer stroma (Vaalamo M 1998), and 
stromal TIMP-3 mRNA in intestine is also found in graft-versus-host-disease (Salmela MT 
2003). TIMP-3 has been proposed to inhibit proteolytic degradation in colon cancer (Zeng Z 
2001), and it prevents destructive activity in processes such as rheumatoid arthritis (Moham-
med FF 2003). Thus, TIMP-3 seems to prevent tissue damage. The specific role of TIMP-3 
in IBD may be due to its ability to inhibit the TNF-α converting enzyme, TACE (Amour A 
1998). TIMP-1 cannot inhibit TACE, and TIMPs -2 and -4 are only capable of weak inhibi-
tion (Amour A 1998). In a human colonic carcinoma cell line, elevated TIMP-3 protein was 
associated with elevated TNF-α levels (Cesaro A 2009). Thus, it seems reasonable to find in-
creased expression of TIMP-3 in IBD, where TIMP-3 may be trying to decrease the amount 
of proinflammatory TNF-α, ultimately to decrease tissue injury. In addition, elevated levels of 
TIMP-3 in paediatric IBD may portray an effort to counteract the activity of elevated levels of 
MMPs. Further study on actual quantity of active MMPs and TIMPs are necessary to qualify 
this. While one would expect false UC and IC samples to have elevated levels of TIMP-3 
versus non-IBD inflammation, it is important to remember the small samples sizes of the two 
groups (n=5, and n=4 respectively). A larger number of samples may have given rise to similar 
differences, and further research would bring light to the issue. As it is, it would seem that 
higher expression of stromal TIMP-3 in paediatric inflammation in the colon points towards 
an IBD etiology.
TIMP-1
TIMP-1 was generally absent from epithelium and stroma in all paediatric samples groups. 
Some samples showed mild stromal expression in UC (n=3, mean 0.25), CD (n=2, mean 0.18) 
and false UC (n=2, mean 0.40) groups.
TIMP-1 protein has been shown to be elevated in adult inflamed IBD (Rath T 2006, Louis 
E 2000), correlating with production of cytokines such as TNF-α and IL-1ß (Louis E 2000). 
Expression in a disease is not always uniform, as in adult active rheumatoid arthritis (Yoshi-
hara Y 1995). While serum levels of TIMP-1 increase, they do not correlate with levels found 
in synovial fluid (Yoshihara Y 1995). Interestingly, in paediatric patients, TIMP-1 mRNA and 
protein are demonstrated in the colon of inflamed and non-inflamed IBD, as well as in normal 
controls, without distinctive differences between the groups (Heuschkel RB 2000). While 
there is no clear explanation for the lack of TIMP-1 here, it may be speculated that TIMP-1 
expression in children and adults differs due to an unknown dissimilarity in pathobiology of 
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adult and paediatric IBD. Here, low levels of TIMP-1 might be compensated for by expres-
sion of TIMP-3.
5.2.2. Epithelial MMP-7 is upregulated in Crohn’s disease
Expression of epithelial MMP-7 was highest in CD samples, compared to UC, IC, and non-
IBD samples (1.09 vs. 0.33, p=0.010; 1.09 vs 0.00, p=0.012; 1.09 vs. 0.45, p=0.033 respective-
ly). Interestingly, when comparing CD samples to UC samples that were rediagnosed as CD 
after follow up (“false UC”), no statistically significant difference existed. Epithelial MMP-7 
did not correlate with serological or faecal inflammation markers. MMP-7 was also found in 
stroma in macrophages, but in neutrophils in only “false UC” samples. Some granulomas in 
CD stained positive for MMP-7 and positive crypt epithelium was seen in a few samples in 
CD, UC and “false UC”.
Although studies of MMP-7 expression in normal intestinal epithelium are contradictory 
(Honda M 1996, Saarialho-Kere UK 1996, Ghosh D 2002, Kirkegaard T 2004), MMP-7 
mRNA and protein are expressed in exocrine glands of healthy epithelium (Saarialho-Kere 
1995b). While MMP-7 protein is generally not found in CD fistulas (Kirkegaard T 2004), 
MMP-7 has been found in epithelium of intestinal ulcers of IBD and non-IBD origin, but 
not in intact epithelium further from the ulcers (Saarialho-Kere UK 1996, Matsuno K 2003). 
Interestingly, epithelial MMP-7 expression did not depend on ulcer depth, but correlated 
positively with neutrophilic inflammation (Saarialho-Kere UK 1996). It is important to note 
that MMP-7 mRNA is increased in both CD and UC in adults (Rath T 2006). Thus it was 
expected that elevated MMP-7 be present in both UC and CD. Since MMP-7 expression 
in epithelium was higher in CD compared to all other patient groups, except in UC samples 
that were rediagnosed as CD during follow up, it does seem that there is something specific 
about paediatric colonic CD epithelium. MMP-7 has been suggested to take part in epithelial 
renewal in intestine (Saarialho-Kere UK 1996), and is also associated with epithelial cell mi-
gration and re-epithelialization in injured lung (Dunsmore SE 1998). In MMP-7 null mice, 
aberrant healing of colonic wounds takes place (Parks WC 1999), and they are susceptible 
to dextran sulfate sodium-induced colitis, possibly by an inability to produce mature cryp-
tidins that would inhibit release of IL-ß1, an important pro-inflammatory cytokine in IBD 
(Ligumsky M 1990, Peterson CG 2007, Shi J 2007). These would imply a protective role for 
MMP-7 in epithelium, but on another note, MMP-7 is not found in migrating enterocytes 
in a foetal gut model (Salmela MT 2004), and MMP-7 protein is also described in dysplastic 
and transformed intestinal epithelium (Matsuno K 2003). MMP-7 was suggested to be a key 
molecule in transformation and a possible marker for malignant phenotype (Matsuno K 2003, 
Rath T 2006), and progression from low-grade to high-grade dysplasia (Newell KJ 2002). 
Thus, MMP-7 is described to have both tissue repair and pathological capabilities. However, 
while for adults the border may be more blurred, the results in paediatric samples suggest 
that MMP-7 could serve as a marker for CD. At a young age, elevation of MMP-7 related 
to dysplasia is not likely, due to the shorter duration of the inflammatory disease. MMP-7 in 
epithelium in CD epithelium may serve some other purpose, such as epithelial regeneration, 
or matrix remodelling. Whatever the role, increased expression of MMP-7 in paediatric co-
lonic epithelium seems to indicate CD, and may aid in differentiating between CD and other 
IBD or non-IBD colonic inflammation.
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Figure 6. Relative expression of M
M
P-10, TIM
P-3 and M
M
P-7 in pediatric IBD and non-IBD samples. Expressed as percentage of samples.
Blue columns, Crohn’s disease samples; red columns, ulcerative colitis samples; green columns, non-IBD samples; orange columns/UC
→
CD, UC 
samples that were rediagnosed as CD during follow-up; purple columns, indeterminate colitis samples; 0 = less than 20 positive cells in a sample; 
1 = 20-100 positive cells; 2 = 101-200 positive cells; 3 = over 200 positive cells. 
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Table 8. MMP- and TIMP-distribution summarised from studies I and II.
CD UC
MMP-8
MMP-1 TIMP-1 MMP-1 MMP-12
MMP-10 MMP-8
MMP-7 TIMP-3 MMP-7 TIMP-3
MMP-12 MMP-10
MMP-1 MMP-1
MMP-7 MMP-7
MMP-8 MMP-8
MMP-9 MMP-9
MMP-10 MMP-10
MMP-12 MMP-12
MMP-26 MMP-26
TIMP-1 TIMP-1
TIMP-3 TIMP-3
Stroma Stroma
neutrophils
macrophages
neutrophils
macrophages
Epithelium Epithelium
neutrophils
macrophages
plasma cells
lymphocytes
neutrophils
macrophages
neutrophils
macrophages
neutrophils
macrophages
macrophages
plasma cells
neutrophils
neutrophils
macrophages
endothelial cells
neutrophils
neutrophils
macrophages
plasma cells
neutrophils
macrophages
macrophages
plasma cells
macrophages
plasma cells
neutrophils
neutrophils
macrophages
endothelial cells
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5.3.	Characterizing	inflammation	in	pouch
The MMP- and TIMP-profiles in pouches were examined in 35 paediatric-onset IBD pa-
tients. All had undergone proctocolectomy, but 7 were rediagnosed with CD subsequent to the 
operation, leaving 28 UC patients. There were no differences in MMP or TIMP profiles when 
comparing samples from patients who experienced recurrent pouchitis (6), from patients who 
reported a single pouchitis episode (13) and from patients who were free from pouchitis (9). 
While the main focus was to examine UC patient pouches, additional comparisons were done 
to assess whether pouches of UC and CD resemble each other. The findings are summarised 
in figure 7, and tables 9 and 10.
5.3.1. MMPs -3, -7, -12 and TIMPs -3 (and -2) were expressed in epithelium and 
stroma
MMP-3
MMP-3 expression in epithelium was present in 22/28 samples (mean 0.93), and in stroma 
in 20 samples (mean 1.25). Expression in stroma was found in plasma cells, macrophages and 
eosinophils, as well as endothelium. Interestingly, histologically assessed grade of inflamma-
tion (Shepherd NA 1987) correlated negatively with epithelial MMP-3 (corr. coeff. -0.614, 
p=0.002).
This is the first report of MMP-3 expression in UC pouch mucosa. The abundant expression 
of MMP-3 in pouch samples suggests that it is an important MMP in the reservoir mucosa. 
Indeed, upregulation of MMP-3 is seen in cultured foetal human small intestine after acti-
vation T-cells (Pender SL 1997). In NEC, both TNF-α mRNA and MMP-3 mRNA and 
protein are upregulated, resulting in severe inflammation in the gut (Pender SL 2003). In a 
murine model of colitis, like MMP-10, MMP-3 is upregulated, and specific inhibition of 
MMP-3 ameliorates this colitis (Kobayashi K 2006). Elevated MMP-3 mRNA and protein 
has been described in inflamed mucosa of UC and CD in adults and children (Bailey CJ 
1994, Heushckel RB 2000, Louis E 2000, Meijer MJ 2007a), and expression also correlates 
positively with the degree of histological inflammation in adults and children (von Lampe B 
2000). However, MMP-3 knockout mice depict slower clearance of bacteria and appearance 
of CD4+T lymphocytes, and MMP-3 seems to aid in controlling pathogenic bacteria in colon 
and mobilizing T-lymphocytes, thus having a role in proper immune response (Li CK 2004). 
Expression of MMP-3 in plasma cells in IBD is not a novel finding (Gordon JN 2008), but 
pouch mucosa has not been investigated before. While earlier reports associate MMP-3 with 
damage in mucosa (Pender SL 1997, Pender SL 2003), there was no difference in MMP 
expression between samples from patients who had, and had not experienced pouchitis. Thus, 
in pouch, MMP-3 may be pathological, but it may also have a homeostatic role, taking part 
in processes such as tissue remodelling. It is important to note that although MMP-3 acts in 
IBD, it is also expressed in other intestinal disorders such as NEC (Pender SL 2003). With 
this in mind, although stromal expression is abundant, the presence of MMP-3 in pouch does 
not confirm pouch mucosa to be IBD-like.
MMP-7
Epithelial MMP-7 was present in all UC samples in pouch (mean 1.36). Stromal expres-
sion was seen in 27/28 samples (mean 1.89), in plasma cells, macrophages, eosinophils and 
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endothelium. Like MMP-3, MMP-7 in epithelium correlated negatively with histologically 
assessed grade of inflammation (corr. coeff. -0.472, p=0.027) (Shepherd NA 1987). The gener-
ous expression of stromal MMP-7, like MMP-3, implies an important role in pouch mucosa. 
MMP-7 mRNA or protein has not been detected in human small intestine before, with the 
exception of gastric mucosa and exocrine epithelium (Saarialho-Kere UK 1995b, Honda M 
1996, Saarialho-Kere UK 1996, Ghosh D 2002, Kirkegaard T 2004, Ravi A 2007). From the 
lack of differences between samples from patients who had suffered pouchitis and those who 
had not, it is assumed that MMP-7 in stroma exists in UC pouches regardless of the level of 
inflammation. Intestinal myofibroblasts are involved in maintaining normal mucosal home-
ostasis and in the healing of gastrointestinal ulcerations (Powell DW 1999), and MMP-7 is 
suggested to help myofibroblasts to grow and function in colitis (Bamba S 2006). MMP-7 in 
pouch mucosa may thus be a player in maintaining mucosal homeostasis. However, cytokines 
such as IL-1 and TNF-α upregulate MMP-7 expression (Marti HP 1992), and MMP-7 can 
further produce bioactive TNF-α from its insoluble form (Mohan MJ 2002). This suggests 
the possibility of MMP-7 self-upregulation in the presence of TNF-α. Studies of MMP-7 
in IBD generally concern expression in epithelial cells, but findings in other tissues propose 
that MMP-7 may have a role in matrix degradation and tissue breakdown and regeneration, 
such as in bone and endometrium (Barille S 1999, Hirota Y 2005). MMP-7 can also activate 
MMP-2 (Sang QA 1996b), which is suggested to have a role in inflammatory and remod-
elling processes in IBD (Gao Q 2005). Indeed, Stallmach et al (2000) report an increased 
amount of MMP-2 mRNA in inflamed pouch, similar to active UC. Interestingly, as MMP-
7 has not been previously found in the ileum, this suggests that pouch mucosa differs from 
that of normal small intestine. However, in UC, stromal expression is not found in colorectal 
mucosa (Matsuno K 2003). MMP-7 has not been reported in pouch before, and while the 
exact pathophysiological role of MMP-7 in the ileal reservoir is not clear, expression in stroma 
seems to be universal in UC pouches. As MMP-7 has not been previously detected in hu-
man ileum and is not found in normal colorectal mucosa, expression does imply a pathologi-
cal process. Since MMP-7 plays a part in TNF-α metabolism, expression in stroma may be 
suggestive of IBD. Although this is speculative, it is enough to warrant further investigation.
MMP-12
MMP-12 was found in epithelium in 20 of the 28 UC samples (mean 0.75), and in stroma in 
24 samples (mean 1.46). Expression in stromal was found in macrophages, plasma cells, eosi-
nophils and intraepithelial neutrophils. In addition, epithelial MMP-12 correlated negatively 
with stool rate (total stool rate per 24h, corr. coeff. -0.485, p=0.010; stool frequency per night, 
corr. coeff. -0.372, p=0.051).
MMP-12 mRNA is not expressed in normal ileal or colonic epithelium in adults (Vaalamo 
M 1998, Salmela MT 2001), but occasional MMP-12 mRNA positive cells have been found 
in intestine of paediatric patients with gastroesophagal reflux (Bister V 2005b). In this as-
pect, pouch mucosa does not resemble normal ileal mucosa. It is important to note, however, 
that MMP-12 is not specific for either small intestine or large intestine disorders, or even 
IBD. Our group has shown MMP-12 mRNA in macrophages in IBD, coeliac disease, and 
necrotizing enterocolitis (Vaalamo M 1998, Bister V 2005a,b). In coeliac disease, MMP-12 
has been put forth to be one of the final steps leading to tissue injury (Ciccocioppo R 2005). 
In DSS-induced colitis in mice, enhanced expression of MMP-12 mRNA occurs (Naito Y 
2004), and MMP-12 knockout mice depict resistance to chemically induced colitis (Pender 
SL 2006). Thus, while a decrease in epithelial MMP-12 may be due to non-specific irritation, 
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MMP-12 in stroma may take part in tissue injury. Since expression is not specific for colitis, it 
cannot be said that pouch mucosa resembles that in IBD, but the existence of MMP-12 does 
not rule it out either. In either case, MMP-12 in pouch is a novel finding. It seems to be an 
important MMP in pouch mucosa, as expression was present in most samples.
TIMP-3
TIMP-3 was present in epithelium in 23 samples in UC (mean 1.04), and in stroma in all 
samples (mean 2.39), in plasma cells and macrophages. Endothelial cells also depicted positiv-
ity for this TIMP. Interestingly, in CD samples, negative correlation was observed between 
calprotectin and epithelial TIMP-3 (corr. coeff. -0.756, p=0.049).
As stated earlier, TIMP-3 mRNA expression is upregulated in IBD stroma and intestinal 
graft-versus-host-disease (Vaalamo M 1998, Salmela MT 2003). TIMP-3 protein upregu-
lation occurs in other pathological processes, such as colorectal carcinoma (Zeng Z 2001). 
However, this study deals with non-dysplastic ileum, and upregulated stromal TIMP-3 ex-
pression also points to an IBD-etiology in paediatric colonic inflammation (study II). Accord-
ingly, in study I, high stromal expression of TIMP-3 in adult CD before immunosuppressive 
treatment was demonstrated. TIMP-3 is implied in IBD processes, in part by indirect inhibi-
tion of TNF-α (Amour A 1998). Cesaro et al report increased TIMP-3 protein expression in 
epithelium of terminal ileum in quiescent versus active CD (Cesaro A 2009). Thus, it would 
seem that TIMP-3 in CD ileum epithelium follows a similar pattern to that in colonic epi-
thelial expression in adult CD (Study I). TIMP-3 is found in epithelium and stroma in both 
healthy colon and ileum (Kirkegaard T 2004, Cesaro A 2009). While epithelial expression in 
UC pouches was not present to a striking degree, the pattern of abundant stromal expression 
mimics that of IBD colon. This suggests a similarity between pouch and IBD mucosal MMP 
expression. 
5.3.2. Epithelial expression of MMP-3 and MMP-7 correlated with inflammation
MMP-3
In cutaneous wounds, MMP-3 mRNA is found in proliferating, but not in migrating ke-
ratinocytes (Saarialho-Kere UK 1994, Vaalamo M 1996). MMP-3 has been suggested to 
impair epithelial healing (Vaalamo M 1996), but it is also suggested to take part in cutane-
ous wound healing, possibly by restructuring novel basement membrane (Saarialho-Kere UK 
1994). While MMP-3 is expressed in intestinal stromal cells such as plasma cells (Gordon 
JN 2008) and fibroblasts (Gunther U 1998), it seems not to be present in IBD epithelium, or 
healthy ileal or colonic epithelium (Saarialho-Kere UK 1996, von Lampe B 2000). Interest-
ingly, MMP-3 was found in ileal enterocytes, and expression associated negatively with histo-
logical degree of infammation (corr. coeff. -0.614, p=0.002). MMP-3 in epithelium may have 
an important role in assisting in epithelial regeneration, such as by activating other MMPs or 
remodelling basement membrane (Suzuki K 1990, Saarialho-Kere Uk 1994). However, in this 
aspect, pouch mucosa differs from IBD mucosa.
MMP-7
An inverse association between epithelial MMP-7 and the histological grade of inflamma-
tion was discovered (corr. coeff. -0.472, p=0.027). While MMP-7 expression in epithelium 
correlates positively with the severity of inflammation in UC and is proposed to be a possible 
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marker for malignant phenotype (Matsuno K 2003, Rath T 2006), MMP-7 knockout mice 
depict inappropriate healing of colonic wounds (Parks WC 1999). In injured lung, MMP-7 
is connected to epithelial cell migration and re-epithelialization (Dunsmore SE 1998). Simi-
larly, MMP-7 is found in epithelium bordering intestinal ulcers in IBD and non-IBD ulcerat-
ing conditions, and is proposed to take part in healing of these lesions (Saarialho-Kere 1996). 
MMP-7 has wide substrate specifity (Miyazaki K 1990, Murphy G 1991, Fosang AJ 1992, 
Imai K 1995), and could take part in remodelling matrix and facilitate migration of entero-
cytes, perhaps by breaking an extracellular matrix barrier (Saarialho-Kere UK 1996). It may be 
that the potential for epithelial regeneration is enhanced in pouches where epithelial MMP-7 
is upregulated. While finding MMP-7 in epithelium in pouch suggests a similarity with UC, 
expression has a dissimilar relationship with histological grade of inflammation, and implies 
an alternative role for MMP-7 in pouch. Ultimately, epithelial expression bears a resemblance 
to IBD, but rather than being a marker for malignant transformation (Matsuno K 2003), it 
may be a beneficial factor in pouch epithelium, promoting epithelial regeneration.
5.3.3. Epithelial and stromal expression of TIMP-2 in UC pouch exceeded that of 
CD pouch
TIMP-2
TIMP-2 was seen in epithelium in 23/28 of the UC samples, and in 23 samples in stroma, 
in plasma cells, macrophages and eosinophils. Interestingly, TIMP-2 in both epithelium and 
stroma were elevated in UC pouches compared to that in CD pouches (mean 0.89 vs. 0.43, 
p=0.035; mean 1.75 vs. 0.86, p= 0.040 respectively).
The majority of the UC samples depicted both stromal and epithelial expression of TIMP-2. 
Interestingly, TIMP-2 is found in normal colonic epithelium, and in lamina propria mononu-
clear cells (Kirkegaard T 2004). TIMP-2 mRNA has been reported in both UC and CD, in 
normal appearing and inflamed mucosa, with no significant difference in expression between 
the two (von Lampe B 2000). TIMP-2 is also found in serum of patient with CD or UC, 
as well as in healthy controls, with no differences in levels between active or inactive disease 
(Kapsoritakis AN 2008). Thus, according to the literature, expression of TIMP-2 is relatively 
similar in both UC and CD. TIMP-2 gene has structural features that suggest it is consti-
tutively expressed (Hammani K 1996). It is not known if these findings apply to pouches, as 
previous studies on MMPs in pouches are scarce. Stallmach et al (2000) show that MMP-2 
mRNA and protein are elevated in inflamed ileal pouches of proctocolectomized UC patients, 
in contrast to similar non-inflamed pouches. Non-inflamed ileum proximal to pouches had 
similar MMP-2 mRNA content as non-inflamed pouches (Stallmach A 2000). Interestingly, 
in chronic cutaneous wounds, the inability of fibroblasts to properly reorganize extracellu-
lar matrix is associated with elevated TIMP-2, resulting in decreased expression of MMP-2 
(Cook H 2001). Similarly, oral mucosal wounds depict more rapid healing versus their cuta-
neous counterparts, and this has been partially explained by the decreased levels of TIMP-2 
in oral mucosal fibroblasts, and accompanying increased levels of MMP-2 mRNA expression 
(Stephens P 2001). In CD, TIMP-2 expression in non-inflamed tissue seems to protect from 
diagnostic or surgical recurrence of the disease, but most likely through inhibition of MMPs 
other than MMP-2 (Meijer MJ 2009). It would seem that MMP-2 and TIMP-2 ratio is 
important in healing processes. Therefore, it is surprising that we neither found any differ-
ences between samples that had experienced pouchitis compared with those that had not, nor 
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any correlation with inflammation indicators and stromal expression of TIMP-2. It may be 
that findings here indeed represent constitutive stromal TIMP-2 expression in ileal pouches 
of UC patients. As previous studies depict some variation of TIMP-2 expression within CD 
(Kossakowska AE 1999), it may be that some unknown factor causes a difference in TIMP-2 
expression in UC and CD pouch. It must be said that there is a notable difference between the 
sizes of the UC (n=28) and CD (n=7) groups, and results must be interpreted carefully. This is 
the first study to assess TIMP-2 in pouches, and further study is warranted. While the exact 
role of TIMP-2 in ileal pouches is unclear, a constitutive expression pattern in UC suggests 
an important physiological role. Findings for TIMP-2 here do not rule out IBD-etiology 
for pouch. However, as it is also expressed in healthy patients, existence of TIMP-2 in UC 
pouches does not confirm IBD-etiology.
 
5.3.4. Lack of MMP-8, -9, -26 and TIMP-1 in pouches
MMP-8
MMP-8 expression was generally absent. Only 1/28 samples showed positivity in stromal 
neutrophils (mean 0.04). 
The role of MMP-8 in IBD has not been extensively studied (Ravi A 2007). MMP-8 protein 
is detected only sporadically in neutrophils in normal colonic and ileal mucosa (Arihiro S 
2001). In mice, MMP-8 mRNA is present in epithelium of IBD colon, and has been proposed 
to take part in ulcer formation by degrading type I collagen (Pirila E 2003). However, in hu-
man UC and CD, MMP-8 is expressed in ulcer base, in neutrophils, but is not found in epi-
thelium (Arihiro S 2001). While MMP-8 is also found in stroma of non-ulcerated inflamed 
IBD, it is absent in areas of fibrosis (Arihiro S 2001). The lack of stromal expression does not 
resemble IBD, but is more in line with normal intestinal mucosa, in both the ileum and colon.
MMP-9
MMP-9 was found in only 9/28 samples in UC stroma, in plasma cells, macrophages, and 
eosinophils (mean 0.32). MMP-9 positive intraepithelial neutrophils were also found. No 
samples stained positive for epithelium.
MMP-9 is generously expressed in IBD, found both in adults and children (Baugh MD 
1999), so it is suprising that expression here was weak. In study I, results depict increased 
expression in adult CD before immunosuppressive treatment. MMP-9 expression in ileum 
is unclear, although occasional MMP-9 positive neutrophils are found in normal duodenum 
(Salmela MT 2001). Interestingly, upregulated MMP-9 mRNA is found in cultured superna-
tants of foetal small intestine (Pender SL 1997), and MMP-9 activity is found in rat ileo-ileal 
anastomosis (Rygl M 2009). However, weak MMP-9 expression does not resemble that found 
in IBD. Thus, with MMP-9 in mind, pouch mucosa is not IBD-like. 
MMP-26
Stroma in 3/28 UC samples showed positivity for MMP-26 in neutrophils and plasma cells 
(mean 0.11). Epithelium in all samples was negative for MMP-26.
In study I, expression of stromal MMP-26 was elevated in CD before treatment. MMP-26 
protein has also been been demonstrated in healthy ileum in linear pattern in the basement 
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Figure 7. Relative expression of M
M
P-3, M
M
P-7, M
M
P-12, and TIM
P-3 in UC pouches, and TIM
P-2 in UC and CD pouches, expressed as 
percentage of samples.
Blue columns, epithelial expression; red columns, stromal expression; 0 = less than 20 positive cells in a sample; 1 = 20-50 positive cells, 2 =50-200 
positive cells; 3 = over 200 positive cells.
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membrane zone, and is associated with epithelial migration (Bister VO 2004). It also found 
in mucosa in NEC and coeliac disease (Bister V 2005a,b). Since MMP-26 may be able to 
activate pro-MMP-9 (Uria JA 2000, Zhao YG 2003), the lack of MMP-26 may result from 
a lack of MMP-9. In any case, one would expect to find more MMP-26 in IBD-like mucosa, 
although expression is not exclusive for IBD. Thus, the results here do not support a similarity 
to IBD. Interestingly, no positivity in beneath epithelium as in intact ileum was found here 
(Bister VO 2004). With this in mind, pouch mucosa does not resemble healthy ileum either, 
suggesting that some pathological event may be suppressing MMP-26 expression.
TIMP-1
TIMP-1 was generally absent, although in some samples, crypt epithelium depicted positivity.
Findings here resemble those in paediatric IBD colon (Study II). Although TIMP-1 pro-
tein is elevated in adult IBD (Rath T 2006, Louis E 2000), TIMP-1 mRNA and protein 
remains unaltered in both inflamed and non-inflamed paediatric IBD, and normal controls 
(Heuschkel RB 2000). Contradictory findings exists for TIMP-1 in IBD intestine (Study I, 
II, Rath T 2006, Louis E 2000), but the lack of TIMP-1 in adult ileal mucosa suggests a dis-
similarity with IBD. 
5.3.5. MMP expression in pouches cannot strictly be classified as IBD, although 
some characteristics of IBD are present
This is the first study to report MMP-3, -7, -9, -12, and TIMP-2 and -3 expression in ileal 
reservoir mucosa. Whereas expression of MMP-3, -7, -12, TIMP-2, and -3 have similarities 
with IBD, that of MMP-8, -9, -26 and TIMP-1 show the opposite. IBD-like etiology of 
pouch MMP-profile cannot be ruled out, but further research, preferably side-by-side analysis 
of healthly ileum, ileal reservoir and pre-proctoctocolectomy mucosa of the same patients, 
might bring more clarity to the issue.
Table 9. Distribution of MMPs and TIMPs in UC pouch.
MMP-3 MMP-7
MMP-8 MMP-9
MMP-12 MMP-26
TIMP-2 TIMP-3
macrophages
plasma cells
plasma cells
macrophages
endothelial cells
eosinophils
neutrophils
eosinophils
plasma cells
macrophages
MMP-3
MMP-7
eosinophils
  endothelial cells
  plasma cells
  macrophages
          MMP-12
Epithelium
TIMP-2
TIMP-3
UC pouch
  macrophages
  plasma cells
  macrophages
  endothelial cells
  eosinophils
  plasma cells
  neutrophils
Stroma
  plasma cells
  eosinophils
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Table 10. Expression of M
M
Ps and TIM
Ps in studies I, II and III.
E, epithelium; s, stroma; baseline, at baseline endoscopy; after immunosuppressive treatment, after treatment with either anti-TNF- α-agent or 
conventional immunosuppressant; -, less than 20 positive cells in any sample; (+) 20-50/100 positive cells in one sample; +, on average 20-50/100 
positive cells in samples; ++, on average 50/100-200 positive cells in samples; +++, on average over 200 positive cells in samples; n.d., not deter-
mined. p=0.030(º), p=0.058(*), p=0.029(**). 
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5.4.	Pyoderma	gangrenosum
By examining the MMP- and TIMP-profiles in pyoderma gangrenosum, the aim was to bet-
ter understand the pathobiology behind this disease, and to assess if there are similarities with 
IBD. The findings are summarised in figures 8 and 9, and table 11.
5.4.1. Expression patterns of TNF-α, MMP-1, -10 and TIMP-3 in PG share similari-
ties with IBD intestinal mucosa
TNF-α 
TNF-α was found in epithelium of 4/28 PG samples, in 3 samples in migrating (mean 0.16), 
and in 2 samples in proliferating (mean 0.11) epithelium. No sample with underlying IBD 
had TNF-α positive epithelium. Stromal cells were positive in all but one PG sample (this did 
not have underlying IBD), in fibroblasts, macrophages and neutrophils (mean 1.20 vs. 1.05 
in non-IBD PG). In acute wounds, migrating keratinocytes expressed TNF-α, as well as oc-
casional stromal neutrophils, fibroblasts and macrophages.
In skin, TNF-α mediated activation of MMPs occurs (Han YP 2001, Han YP 2002), and 
TNF-α has been proposed to play a role in keratinocyte migration, through an MMP-9 
dependent pathway (Scott KA 2004). However, wound fluid from healing chronic cutaneous 
ulcers contains less TNF-α than non-healing ones (Trengove NJ 1996), and TNF-α has been 
suggested to impair wound healing, possibly by inefficient wound contraction (Goldberg MT 
2007). Unlike findings here, TNF-α expression in keratinocytes bordering cutaneous heal-
ing and non-healing wounds has been reported to be similar (Tian YW 2003). Interestingly, 
stromal expression was present in almost all PG samples, and this may be a contributing factor 
to the chronic nature of PG. Lack of epithelial expression may have a similar role. In IBD 
mucosa, the number of TNF-α-positive cells, such as macrophages, is elevated (Murch SH 
1993). Indeed, anti-TNF-α agents have been successful in treating both PG and IBD (Kohn 
A 2004, Kouklakis G 2005, Juillerat P 2007, Cucchiara S 2008). Stromal expression of TNF-α 
in PG resembles that of IBD intestine, and suggests similar mechanism in the pathobiology 
of the two disorders.
MMP-1
MMP-1 was found in 21/24 samples in epithelium, in migrating cells in 6 samples, and pro-
liferating cells in 20 samples. Stromal expression was found in fibroblasts and macrophages in 
20 samples. Expression patterns of MMP-1 in migrating and proliferating epithelium and in 
stroma did not differ statistically between IBD and non-IBD PG (mean 0.00 vs. 0.32; 1.00 
vs. 0.89; 1.60 vs. 1.47 respectively). In acute wounds, positivity was found only in migrating 
keratinocytes and occasional stromal cells, not in the proliferating zone of keratinocytes.
MMP-1 has a major role in keratinocyte migration in the healing of cutaneous wounds 
(Pilcher BK 1997). MMP-1 mRNA is found in migrating keratinocytes in both acute and 
chronic cutaneous wounds (Saarialho-Kere UK 1994, Vaalamo M 1996), and in stroma of 
chronic wounds (Saarialho-Kere UK 1994). Further, MMP-1 mRNA is found in migrating 
enterocytes in ishemic colitis and in a foetal gut model (Salmela MT 2004), but is not seen in 
intestinal ulcerations of IBD origin (Saarialho-Kere UK 1996). MMP-1 protein is, however, 
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expressed in stromal cells in IBD, such as macrophages and fibroblasts (von Lampe B 2000, 
Arihiro S 2001, Di Sabatino A 2003), although the number of positive cells is lower in unin-
volved IBD mucosa (Di Sabatino A 2003). Here, presence of MMP-1 in stroma is in line with 
findings in IBD intestine, but resembles chronic cutaneous ulcers as well. As for epithelial 
expression, it is assumed that if PG ulcerations resembled IBD, the migrating keratinocytes 
would lack MMP-1. Interestingly, while no statistical difference could be observed in expres-
sion of MMP-1 in migrating keratinocytes between non-IBD and IBD related PG ulcers, 
keratinocytes in the migratory area were negative for this MMP in the latter. This could point 
toward a common mechanism in cutaneous PG and intestinal healing, especially in patients 
with underlying IBD. 
MMP-10
Epithelial MMP-10 was present in 21/24 samples, in the migrating zone in 11 samples, and 
in the proliferating area in 20 samples. MMP-10 in epithelium was present in 4/5 samples 
with underlying IBD, in 3/5 samples in migrating (mean 0.60 vs. 0.42 in non-IBD PG), 
but in 4/5 samples in proliferating keratinocytes (mean 1.20 vs. 1.00 in non-IBD PG). In 
stroma, MMP-10 was found in 18/24 samples in macrophages, fibroblasts and endothelial 
cells, whereas all samples with underlying IBD depicted stromal expression (mean 1.20 vs. 
1.00 in non-IBD PG). The acute wounds all expressed MMP-10 in migrating keratinocytes, 
but positive stromal cells were found only occasionally.
MMP-10 mRNA is present in enterocytes bordering IBD ulcers, but is not found in prolif-
erating enterocytes, or intact epithelium further away from intestinal ulcerations (Vaalamo 
M 1998). MMP-10 mRNA is also found in migrating enterocytes in a foetal gut model 
and cultured intestinal epithelial cells (Salmela MT 2004). Interestingly, cytokines such as 
TNF-α and IL-1ß upregulate MMP-10 mRNA expression in these cultured intestinal cell 
lines (Salmela MT 2004). In addition to normal colon and ileum, colorectal adenomas and 
carcinomas are also negative for this mRNA (Vaalamo M 1998, Newell KJ 1994). MMP-10 
mRNA in epithelium is not specific for IBD though, and is also observed in other processes 
such as ischemic colitis (Vaalamo M 1998, Salmela MT 2004). As in intestine, normal skin 
does not express MMP-10 mRNA (Saarialho-Kere UK 1994). In cutaneous wounds, MMP-
10 mRNA is found in migrating keratinocytes in both acute and chronic lesions, and seems 
to colocalize with MMP-1 mRNA (Saarialho-Kere UK 1993, Saarialho-Kere UK 1994, 
Vaalamo M 1996). Similarly, MMP-10 protein has been reported in migrating keratinocytes 
in acute wounds (Rechardt O 2000). In this aspect, PG shares similarities with both intestinal 
and cutanous ulcers that resemble each other. MMP-10 mRNA is found in stroma in a T-cell 
explant model of mucosal destruction, and is suggested to contribute to mucosal degradation 
and shedding of epithelium (Salmela MT 2002). Interestingly here, acute wounds depicted 
only occasional expression of MMP-10 in stroma, and chronic and acute cutaneous wounds 
have been reported negative for stromal mRNA (Saarialho-Kere UK 1994, Vaalamo M 1996, 
Rechardt O 2000). It would seem that abundant expression of MMP-10 in stroma of PG 
differs from acute or chronic cutaneous wounds, pointing towards an alternative pathobiology. 
Further, in a murine model of colitis, MMP-10 mRNA is upregulated, and expression can ad-
ditionally be increased by stimulation with TNF-α (Kobayashi K 2006). In study II, abundant 
stromal expression of MMP-10 protein was found in both IBD and non-IBD colon. MMP-
10-positive stromal macrophage- and lymphocyte-like cells are found in intestinal ulcer stro-
ma, so the stromal pattern found in PG is more in line with an intestinal profile (Vaalamo 
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M 1998). It must be said that stromal expression is found in other intestinal conditions as 
well, such as ischemic colitis, not only IBD (Vaalamo M 1998). While epithelial expresson of 
MMP-10 resembles that in both cutaneous wounds and intestinal ulcers, expression in PG 
stroma is more like that in intestinal ulcers, not only IBD. 
TIMP-3
TIMP-3 expression was fairly universal in both migrating (mean 1.00 vs. 0.87 in non-IBD 
PG) and proliferating (mean 1.00 vs 0.93 in non-IBD PG) epithelial zones in PG (in 18/20 
and 19/20 samples respectively). All PG samples with underlying IBD (5/5) depicted posi-
tivity for TIMP-3 in both epithelial zones. Abundant expression in stroma was also present 
throughout the PG samples (20/20 samples), in fibroblasts, macrophages and neutrophils 
(mean 1.60 vs 2.20 in non-IBD PG). However, acute wound keratinocytes did not generally 
express TIMP-3 in the migrating tip, but only further away from the ulcer.
In cutaneous wounds, TIMP-3 protein is found in proliferating epithelium and stroma of 
both acute and chronic wounds, and may be necessary for proper re-epithelialization (Vaala-
mo M 1999). However, TIMP-3 mRNA is only found in acute wound epidermis (Vaalamo 
M 1999). However, TIMP-3 has not been detected in the migrating tip of either acute or 
chronic wounds (Vaalamo M 1999). This is in agreement with the present results in acute 
wounds. Interestingly, as so many of the PG samples here depict expression in migrating 
keratinocytes, expression in that area seems to be the rule rather than an exception. Earlier, 
we reported TIMP-3 mRNA negative epithelium in IBD ulcers (Vaalamo M 1998), but 
later found TIMP-3 positive enterocytes in CD and UC (studies I, II). As with cutaneous 
wounds (Vaalamo M 1999), there may be a similar discrepancy between mRNA and protein 
expression. It is important to note that TIMP-3 protein is expressed in normal colon epithe-
lium (Zeng Z 2001), and a trend for increased epithelial TIMP-3 expression occurred in CD 
along with treatment (study I), reflecting earlier results in quiescent disease (Cesaro A 2009). 
Abundant TIMP-3 expression in stroma is a common feature in IBD. Our group has reported 
upregulation of stromal TIMP-3 mRNA in IBD ulcers (Vaalamo M 1998) and in another 
T-cell mediated inflammation, graft-versus-host-disease (Salmela MT 2003). In study I, there 
is elevated stromal TIMP-3 in CD before immunosuppressive treatment: in study II, stromal 
expression associates with colonic inflammation in paediatric IBD. However, in skin, stromal 
expression of TIMP-3 is most pronounced in ulcers of a chronic nature (Vaalamo M 1999). 
While stromal and epithelial expression is reported in IBD intestine as well as in cutaneous 
lesions, finding TIMP-3 positive migratory keratinocytes suggests a difference compared to 
other types of cutaneous wounds. This may be a specific feature of PG. However, the role of 
TIMP-3 in PG is still unclear. It has been suggested to retard wound healing in PG, possibly 
by inhibiting MMPs important in migration (Bister V 2007). This may be the case for stromal 
TIMP-3, and possibly even for epithelial TIMP-3 in PG, but epithelial TIMP-3 may also 
play some protective role as suggested for IBD (study I). However, while TIMP-3 expression 
resembles IBD intestine, expression in migrating keratinocytes specifically suggests PG to 
have a different pathology than other chronic wounds.
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Figure 8. Relative expression of TNF-α and M
M
P-1 in PG, expressed as percentage of samples.
Non-IBD/blue columns, PG with no underlying IBD; IBD/red columns, PG with underlying IBD; 0 = less than 10 positive cells; 1 = 10-20 posi-
tive cells; 2 = 20-50 positive cells; 3 = over 50 positive cells. 
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Figure 9. Expression of M
M
P-10 and TIM
P-3 in PG, displayed as percentage of samples.
Non-IBD/blue columns, PG with no underlying IBD; IBD/red columns, PG with underlying IBD, 0 = less than 10 positive cells; 1 = 10-20 posi-
tive cells; 2 = 20-50 positive cells; 3 = over 50 positive cells.
81
5.4.2. Expression profiles of MMP-7, and -26 do not resemble IBD, and expres-
sion of MMP-8, -9 and TIMP-1 are inconclusive
MMP-7
Epithelial expression of MMP-7 was found in only 1/20 samples: in the proliferating zone 
of a PG sample with underlying IBD (mean 0.67 vs. 0.00 in non-IBD PG). Expression in 
stromal cells was found in 4/20 PG samples, where one had underlying IBD (mean 0.33 vs 
0.18 in non-IBD PG).
MMP-7 mRNA and protein are absent from the epithelium of chronic cutaneous wounds 
(Vaalamo M 1996, Impola U 2005), and acute wound keratinocytes have been shown to be 
negative for this mRNA as well (Vaalamo M 1996). In healthy skin, MMP-7 mRNA and 
protein expression is restricted to eccrine sweat glands and ductal epithelial cells of dermal 
appendages (Saarialho-Kere UK  1995b). However, both are found in intestinal ulcerations 
in bordering enterocytes in ulcers of IBD and non-IBD etiology, and MMP-7 mRNa is 
upregulated in an intestinal epithelial cell line by proinflammatory cytokines such as IL-1ß 
and TNF-α (Saarialho-Kere UK 1996, Matsuno K 2003, Salmela MT 2004). MMP-7 is not 
found in intact epithelium or stroma in normal intestine (Saarialho-Kere UK 1996). Earlier 
reports state that MMP-7 is not detected in stromal cells in IBD intestine (Saarialho-Kere 
UK 1996, Matsuno K 2003). In adult CD (study I), there was generally no expression of 
MMP-7 in CD stroma, and stromal expression was also rare in paediatric IBD (study II). 
Epithelial MMP-7 however, was found in colonic epithelium in paediatric CD, but was rare 
in paediatric UC and adult CD (study I, II). It would seem that lack of MMP-7 in PG has 
higher resemblance to other cutaneous wounds, but does not automatically dismiss similarities 
with IBD intestine.
MMP-26
MMP-26 was found in epithelium in 10/24 samples, only in the area representing migrating 
keratinocytes. Of the PG samples with underlying IBD, 3 samples depicted positive migra-
tory keratinocytes (mean 0.60 vs. 0.37 in non-IBD PG). PG samples that were immuno-
suppressed expressed more MMP-26 in migrating keratinocytes than PG samples that were 
not (mean 0.73 vs. 0.15, p=0.005). Stromal expression was generally absent. Acute wounds 
depicted MMP-26 positive migrating keratinocytes.
MMP-26 protein is not found in the epidermis of healthy skin (Ahokas K 2005). In chronic 
and normally healing wounds, MMP-26 is expressed in migrating keratinocytes, and it is 
suggested to take part in migration, possibly by degrading fibronectin and type IV collagen 
(Uria JA 2000, Ahokas K 2005). Higher expression of MMP-26 in immunosuppressed PG 
keratinocytes may further support the favourable role of MMP-26 in wound healing. How-
ever, as MMP-26 is also expressed in chronic cutaneous wounds (Ahokas K 2005), it does not 
seem to serve as a differentiating marker between acute and chronic ulcers. Interestingly, while 
our group earlier reported MMP-26 in migrating enterocytes bordering intestinal wounds 
in UC, this phenomenon was not observed in CD (Bister VO 2004). Expression in our PG 
patients with underlying IBD did not follow this pattern. Of the three showing MMP-26 in 
keratinocytes, two had underlying CD and one had UC. Also, samples negative for migrating 
keratinocytes included patients with both underlying CD and UC. In addition, MMP-26 
was not found in epithelium in either adult CD or paediatric IBD (study I, II). Expression 
of MMP-26 protein is found in the ileum and colon, in the basement membrane area below 
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epithelium (Bister VO 2004). In necrotizing enterocolitis, with almost intact morphology, 
epithelial cells depict positivity for MMP-26 protein, and expression is downregulated in 
the more injured and inflamed NEC epithelium (Bister V 2005a). MMP-26 in epithelium 
presents rather as a protective and regenerative factor than a destructive MMP. In the work 
with paediatric IBD (study II), only rare stromal MMP-26 expression was found, whereas in 
adult CD (study I), expression was present in stroma in nearly all samples, and decreased with 
treatment. Differential expression of MMP-26 in stroma in IBD may be due to differences in 
the disease pathology in paediatric and adult patients. Stromal cells are negative in both acute 
and chronic cutaneous wounds (Ahokas K 2005). Although MMP-26 has been reported in 
enterocytes (Bister VO 2004), the expression pattern of MMP-26 does not resemble intestinal 
IBD, but rather that of cutaneous wounds.
MMP-8
MMP-8 was absent from epithelium of all samples. In PG, stromal neutrophils were positive 
for this MMP in 12 samples; 3 of these samples had underlying IBD (mean 0.80 vs. 0.84 in 
non-IBD PG).  Acute wounds depicted only occasional positive neutrophils.
MMP-8 is abundant in tissue extracts of healing cutaneous wounds (Nwomeh BC 1998). 
However, later reports describe elevated levels in chronic wounds compared to healing cuta-
neous wounds (Nwomeh BC 1999, Lobmann R 2002). In intestine, MMP-8 is expressed in 
neutrophils in IBD ulcer bases (Arihiro S 2001), and MMP-8 has been proposed to contrib-
ute to ulcer formation by degradation of type I collagen (Pirila E 2003). MMP-8 expression 
in PG seems to resemble both chronic cutaneous wounds and IBD intestine. Thus, this MMP 
does not prove or deny similarities to IBD-like etiology of PG wounds.
MMP-9
MMP-9 expression was detected in epithelium in 8 of the 24 PG samples. In samples with 
underlying IBD, weak expression was present: only 2 of these samples expressed MMP-9 in 
migrating keratinocytes (mean 0.40 vs. 0.26 of non-IBD PG), with none in proliferating epi-
thelium (mean 0.00 vs. 0.11 of non-IBD PG). In stroma, MMP-9 was observed in 23 of the 
PG samples, in macrophages and neutrophils, and in all samples with associated IBD (mean 
2.00 vs. 1.68 of non-IBD PG). In acute wounds MMP-9 was found in migrating epithelium.
Chronic cutaneous wound keratinocytes rarely express MMP-9 protein, but it is instead abun-
dantly found in macrophages and neutrophils in stroma (Mirastschijski U 2002). In normally 
healing wounds, expression of MMP-9 protein is mainly present in migrating keratinocytes 
(Mirastschijski U 2002, Saarialho-Kere UK 2002). Mirastschijski et al (2002) suggest that ab-
sence of MMP-9 in keratinocytes at the wound margin describes non-migratory phenotype, 
and others agree that MMP-9 may take part in human keratinocyte migration and granulation 
tissue remodelling (Salo T 1994). Interestingly, Scott et al (2004) propose that TNF-α regu-
lates epithelial expression of MMP-9, as well as keratinocyte migration through an MMP-9 
dependent pathway. Contradictory to this, MMP-9 deficient mice portray accelerated corneal 
and cutaneous wound healing (Mohan R 2002). In a murine model of colitis, MMP-9 is up-
regulated in epithelium, and may have a role in impaired wound healing and cell attachment 
(Castaneda FE 2005). In IBD mucosa, MMP-9 is generously expressed (Bailey CJ 1994, 
Baugh MD 1998, Baugh MD 1999), and presents as being important in tissue destruction 
(Baugh MD 1999, Tarlton JF 2000). The number of MMP-9 positive neutrophils is increased 
in a mouse model of colitis (Castaneda FE 2005), and in humans, expression of this MMP in 
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serum and PMNL cells in mucosa decreases with treatment (Gao Q 2007). Similarly, in study 
I, treatment with immunosuppressive agents indeed reduces expression of stromal MMP-9 in 
CD. While the actions of MMP-9 in PG epithelium are elusive, weak expression may con-
tribute to the chronic nature of the ulcer. A general lack of epithelial MMP-9 was found also 
in IBD (studies I and II). In summary, rare epithelial MMP-9 expression resembles findings 
in other chronic cutaneous wounds as well as those in both IBD and non-IBD intestine, and 
is not in itself suggestive of IBD-like etiology. Abundant stromal expression also resembles 
both IBD mucosa and chronic cutaneous wounds. MMP-9 expression thus does not deny or 
confirm IBD-like etiology of PG.
TIMP-1
TIMP-1 was not found in any sample in epithelium. Stromal expression of TIMP-1 was 
detected in macrophages, fibroblasts and endothelial cells in 19 of 24 samples; in 3/5 PG with 
underlying IBD (mean 0.60 vs. 1.00 in non-IBD PG). In acute wounds, TIMP-1 was only 
expressed by fibroblasts in stroma.
While TIMP-1 is not found in epithelium of chronic wounds, acute wounds express TIMP-1 
mRNA in proliferating keratinocytes (Vaalamo M 1996, Vaalamo M 1999). Interestingly, in 
human burn wounds, TIMP-1 mRNA is present in migrating keratinocytes as well, although 
the strongest signal is found in proliferating epithelium (Stricklin GP 1993). TIMP-1 has ke-
ratinocyte growth promoting capabilities (Lambert E 2004), and may be necessary for proper 
re-epithelializaton (Vaalamo M 1999). Normally healing wounds express TIMP-1 mRNA in 
stromal cells (Vaalamo M 1999). In intestine, TIMP-1 mRNA is abundantly expressed in the 
ulcer base, but no signal is detected in epithelium (Saarialho-Kere UK 1996). Elevated protein 
expression is also found in inflamed UC mucosa (Rath T 2006). In IBD mucosa, TIMP-1 
mRNA correlates with the histological degree of inflammation, and is specifically associated 
with ulcerations (von Lampe B 2000). The lack of TIMP-1 in epithelium could partly explain 
the chronic nature of PG. However, the expression pattern fits both chronic cutaneous wounds 
and intestinal wounds. While it does not support, it neither denies a similar mechanism be-
hind PG and IBD intestinal ulcers.
Table 11. Expression of MMPs and TIMPs in PG.
 
e-m, keratinocytes in migratory area of epithelium; e-p, keratinocytes in proliferatory area 
of epithelium; s, stroma; -, less than 10 positive cells in any sample; (+), between 10 and 20 
positive cells in only one sample; +, between between 10 and 20 positive cells in sample on 
average; ++, between 20-50 positive cells in sample on average; +++, over 50 positive cells in 
sample on average.
e-m e-p s e-m e-p s e-m e-p s e-m e-p s e-m e-p s
IBD PG - + ++ - (+) (+) - - + + - ++ + ++ ++
non-IBD PG + + ++ - - + - - + + + ++ + + +
e-m e-p s e-m e-p s e-m e-p s e-m e-p s
IBD PG + - - - - + + + ++ - - ++
non-IBD PG + - (+) - - + + + +++ + + ++
MMP-10
MMP-26 TIMP-1 TIMP-3 TNF-α
MMP-1 MMP-7 MMP-8 MMP-9
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6. Conclusions
Matrix metalloproteinases are important proteases participating in a variety of physiologi-
cal processes. They have been connected with beneficial actions in skin and intestine, but are 
also represented in inflammatory and malignant developments in both.  Although reports on 
MMP actions in the gut are being published worldwide, the pathobiology behind inflamma-
tory bowel diseases is still unclear.
This thesis examines the MMP and TIMP profiles in IBD inflammation in both adult and 
paediatric patients. The aim is to characterize PG and to find possible links between intestinal 
IBD inflammation and this cutaneous manifestation. It must be said that no specific MMP or 
TIMP in these studies proved more important than the others. Rather, by looking at several 
MMPs, we find interesting shifts in expression between different disorders. Further, there 
were MMP profiles related to immunosuppressive treatment, suggesting pathophysiological 
roles for MMPs in IBD.
In moderate to severe CD, patients may require anti-TNF-α agents, or a combination of cor-
ticosteroids and conventional immunosuppressants to reach remission. Here it was found that 
after treatment with these agents, samples depicted decreased numbers of stromal MMP-9 
and MMP-26 neutrophils. In addition, stromal TIMP-1 and TIMP-3 decreased. While re-
duction in MMP-26 and MMP-9 may directly aid in reducing inflammation in mucosa – due 
to reduced proteolysis – it is suggested that the reduction in TIMPs was a net effect, rather 
than a direct response to treatment. Possibly the TIMPs were initially elevated in an effort to 
combat elevated MMP-9 and -26. While it is suggestive that specific inhibition of MMP-9 
and MMP-26 may be beneficial in treating CD, it is expected that inhibiting TIMP-1 and 
TIMP-3 would be unlikely to produce the same effect.
Differential diagnosis in paediatric IBD patients with pancolitis can be challenging. However, 
increased epithelial MMP-10 and stromal TIMP-3 expression is suggestive of IBD, and could 
be used to differentiate between paediatric IBD and non-IBD colonic inflammation. In addi-
tion, increased MMP-7 in epithelium was indicative of CD. Thus, epithelial MMP-7 may in 
the future assist in differentiating CD from other types of colonic inflammation. 
To the best of our knowledge, this is the first report of MMP-3, -7, -9, -12, and TIMP-2 and 
-3 in pouch mucosa. Expression of MMP-3, -7, -12, TIMP-2, and -3 have similarities with 
IBD, but that of MMP-8, -9, -26 and TIMP-1 are contradictory. The mechanism bringing 
about the MMP- and TIMP-profile in pouch mucosa may be IBD-like, but pouch mucosa 
cannot be classified as IBD mucosa per se. However, the results implicate a number of MMPs 
in pouch pathobiology not previously reported. Further study is necessary to fully characterize 
pouch, and examine the actions of the MMPs in the ileal mucosa.
In PG, it is known that several patients suffer from underlying systemic ilnesses, IBD being 
a common one. Thus, it could be speculated that there are similarities between IBD intestinal 
and PG cutaneous inflammation. Indeed, several similarities with IBD instestinal mucosa 
were discovered, while specifically stromal TNF-α and MMP-10, and epithelial MMP-1 and 
TIMP-3 contradicted cutaneous patterns of expression. While other differences remain, these, 
together with PG responsiveness to IBD treatment (Levitt MD 1991, Janowitz HD 1998), 
support common mechanisms of inflammation.
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